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ABSTRACT 
Rheumatoid Arthritis (RA) is a complex, systemic autoimmune disorder characterized by 
chronic inflammation in small joints in hands and feet. It is a common disease that if 
untreated leads to joint destruction, disability, comorbidities and a reduced lifespan. Both 
genetic and environmental factors contribute to disease pathogenesis that in the majority of 
patients is characterized by the occurrence of antibodies against citrullinated proteins 
(ACPA). The strong genetic association with certain MHC class II alleles led to autoreactive 
T cells being assigned a major role in the course of disease. Today, citrulline-specific CD4+ 
T cells are regarded the perfect target for antigen-specific immunotherapy and have so far 
been investigated in a handful of studies. The focus of this thesis was therefore to expand our 
knowledge of citrulline-reactive T cells with a specific emphasis on their phenotype as well 
as the interaction with their cognate peptide-HLA complexes on antigen-presenting cells.  
We have examined functional T cell responses to native and citrullinated epitopes derived 
from the candidate antigen α-enolase and compared their relevance in peripheral blood of 
patients with different RA-associated HLA-DR alleles. While HLA-DRB1*04:01 and *04:04 
presented a similar set of peptides, a clear bias in functional responses towards citrullinated 
epitopes was observed in HLA-DRB1*04:01 patients. When analysing crystal structures of 
both native and citrullinated versions of two α-enolase epitopes in complex with HLA-
DRB1*04:01, we found the citrulline residues at peptide positions p-1 and p2, respectively. 
In both cases the citrulline was not involved in binding to the HLA molecule but instead 
pointed upwards readily available for interaction with the TCR. Particular recognition of 
these citrullinated epitopes by the T cells is thus based on the creation of neoantigens. Using 
HLA class II tetramer technology, we even detected cross-reactive T cells in some patients 
recognizing both native and citrullinated version of the epitope with citrulline at position p-1 
implicating the existence of TCRs with different docking patterns towards these pHLA 
complexes. When comparing frequencies of T cells reactive to either of the two versions, we 
found memory T cells specific for the citrullinated version enriched in the synovial fluid 
compared to peripheral blood. Additionally, by successfully combining HLA class II tetramer 
sorting with single cell RNAsequencing, we could compare the transcriptional profile of 
citrulline- versus virus-specific CD4+ T cells in peripheral blood and synovial fluid of RA 
patients. Here, we repeatedly found genes associated with cytolytic and cytotoxic features 
upregulated in the citrulline-specific T cells both in blood and synovial fluid. Furthermore, 
we developed a multi-tetramer staining panel that allows the simultaneous assessment of 
multiple specificities making it applicable for longitudinal monitoring of T cells in clinical 
samples. Using this tool to examine the frequency and phenotype of T cells specific for eight 
citrullinated peptides from four RA candidate antigens, we could show that the frequencies of 
citrulline-specific CD4+ T cells in early RA patients decline upon disease improvement.  
In summary, our data demonstrate that autoreactive citrulline-specific T cells are present in 
RA patients both early and late in the disease course and that the breach of tolerance includes 
several non-related autoantigens. 
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1 BACKGROUND 
1.1 THE IMMUNE SYSTEM 
Eukaryotic organisms have over the course of time developed a complex and well regulated 
network of cells, tissues, organs and biological processes, that protects the body from disease 
and defends it against invading pathogens as well as infectious and harmful substances. This 
host defense system, the immune system, can generally be divided into two parts, the innate 
and the adaptive immunity. Both subsystems work in cooperation in identifying and fighting 
a variety of threats, including bacteria, fungi, parasites and viruses while at the same time 
regulating its own effector mechanisms and generating immunological memory.  
The innate immune system is regarded as the earliest, nonspecific line of defense against 
invading pathogens whereas the adaptive immunity provides a slower, but highly specialized 
response and is even able to establish immunologic memory, which is of importance in case 
of reinfections. The cellular basis of both the innate and adaptive immune response is 
leukocytes or white blood cells that originate from hematopoietic stem cells in the bone 
marrow. Besides the bone marrow and the thymus, the primary lymphoid organs, where 
maturation of adaptive immune cells takes place, there are several other tissues and organs, 
like the spleen and lymph nodes that together with a network of conducting vessels make up 
the lymphatic system. All of these tissues and organs play a role either in leukocyte 
generation, maturation or activation. 
 
1.1.1 Innate immunity 
The defense mechanisms of the innate immune system include physical and chemical barriers 
like skin, mucosa, antimicrobial peptides and proteins as well as humoral and cellular 
components. Cells belonging to the innate immune system are dendritic cells (DCs), 
granulocytes (neutrophils, eosinophils, basophils and mast cells), natural killer (NK) cells, 
monocytes and macrophages. Some of these cells, like neutrophils, DCs and macrophages 
have phagocytic activity and recognize potential pathogens via specific pattern recognition 
receptors (PRRs) [1], such as toll-like receptors (TLRs) or nucleotide-binding 
oligomerization domain (NOD)-like receptors [2-4]. The structures recognized by these PRRs 
are highly conserved and either present on the surface of most pathogens, the pathogen-
associated molecular patterns (PAMPs) or, as the name damage-associated molecular patterns 
(DAMPs) implies, released by stressed and necrotic cells upon tissue damage [5]. A 
triggering of PRRs by PAMPs or DAMPs does not only initiate the phagocytosis of the 
pathogen and the release of anti-microbial mediators, like hydrogen peroxide (H2O2) or 
nitrogen oxide (NO) [6], but also activates nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), a transcription factor that induces the expression of genes 
encoding e.g. pro-inflammatory cytokines like interleukin (IL)-1β, IL-6, IL-8, interferon 
(IFN)-γ and tumor necrosis factor (TNF) [7-11]. These in turn are then able to instruct and 
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recruit other immune cells like neutrophils and monocytes, but interestingly even activate and 
help control adaptive immunity [12]. Other innate immune cells do not have phagocytic 
capacity, like eosinophils, basophils and mast cells, and instead “fight” pathogens by 
releasing granules containing toxic proteins, enzymes and inflammation-inducing molecules 
[13]. In addition NK cells possess cytotoxic granules containing perforin-1 and granzymes 
and can upon cell-cell contact recognize abnormal cells like tumor or virus-infected cells, and 
release their granule content onto the surface of these target cells [14, 15]. 
Besides this cellular part, there is also the humoral part of the innate immune system 
consisting of a number of proteins circulating in the blood. These include naturally occurring 
antibodies, pentraxins, like C-reactive protein (CRP) as well as components of the 
complement and contact cascades [16]. Due to their constant presence in the circulation, these 
innate proteins can act as principal mediators of inflammatory responses to pathogens and 
their increased concentration in the serum is often used as a marker of infection, 
inflammation and tissue damage. Once a microorganism is recognized by e.g. naturally 
occurring antibodies or pentraxins, complement proteins, most of them being enzymes or 
zymogens, become sequentially activated in an enzyme cascade. There are three different 
pathways leading to complement activation: 1) the antibody-mediated classical pathway, 2) 
the mannan-binding lectin pathway and 3) the alternative pathway triggered by spontaneous 
hydrolysis of the C3 convertase. All three pathways lead to killing of the pathogen or infected 
cell and this either happens directly via formation of the pore-forming membrane attack 
complex (MAC) on the surface of the pathogen by the complement components C5b-C9 and 
the creation of an osmotic leak [17] or indirectly via opsonisation of the pathogen by 
particular complement proteins, e.g. C3b and C4b that facilitate recognition and phagocytosis 
by neutrophils or macrophages. Anaphylatoxins like C3a, C4a and C5a, are originating from 
cleavage of certain complement components and affect the local vascular permeability 
making it easier for the above-mentioned cells as well as other leukocytes even from the 
adaptive system to enter the area of the insult. At the same time it is easier for recently 
activated DCs that have taken up pathogen and started processing it to leave and migrate to 
the draining lymph nodes where they mature and subsequently present the antigen to and 
instruct cells from the adaptive immune system [18]. Together with NK cells, these antigen-
presenting cells (APCs) create the link between the innate and the more advanced adaptive 
immune response. 
 
1.1.2 Adaptive immunity 
The adaptive or acquired immune response is the second line of defense attacking and 
eliminating pathogens that evaded or overpowered the innate host defenses. It is usually 
triggered by signals received from innate immune cells such as pro-inflammatory cytokines 
or chemokines that lead to activation and chemotaxis of adaptive immune cells. Additionally, 
the direct engagement of APCs, like DCs or macrophages, with T lymphocytes leads to the 
activation of the lymphocyte and thus the initiation of an adaptive immune response. While 
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the innate immune response occurs within minutes and hours after a pathogenic insult, it 
takes several days for an adaptive immune response to be fully mounted [19]. Nevertheless, 
this response will then, in contrast to the innate one be more effective, as it is highly specific 
for the respective pathogen and will moreover have contributed to the creation of 
immunological memory and long-lasting immunity so that in case of a reinfection with the 
same microorganism the reaction can be both faster and more intense. Another feature of the 
adaptive immunity is that it can discriminate between self and non-self and specifically 
targets foreign structures. Same as for the innate immunity, adaptive immune responses are 
made up of a cellular (B and T lymphocytes) and a humoral (antibodies) component.  
Antigen presentation and recognition 
B and T cells have highly variable and specialized antigen receptors on their cell surfaces that 
are generated during lymphocyte development by somatic or V(D)J recombination. The 
genetic rearrangements occurring during this process lead to a highly diverse selection of 
immune cells which makes it possible for the organism to respond to virtually any antigen it 
gets exposed to [19]. 
T cell receptors (TCRs) are heterodimers composed of two single protein chains expressed on 
the cell surface of T cells. Most T lymphocytes possess αβ-TCRs consisting of an alpha and a 
beta chain while a minority, around 5% express γδ-TCRs made up of a gamma and a delta 
chain. Each TCR chain is composed of a constant and a variable domain with the 
combination of the two variable domains, e.g. Vα and Vβ, forming the antigen-recognition 
site. The highest variability between TCRs can be found in three specific regions in the 
variable domains of both TCR chains, the so-called hypervariable or complementarity 
determining regions (CDRs). These regions form specific loops that make contact with both 
the HLA molecule and the antigenic peptide and are crucial for recognition (Figure 1).  
 
 
 
	
	
Figure	1:	The	structure	of	the	extracellular	part	of	an	αβ-T	
cell	receptor	(PDB-ID:	1J8H,	[20]).	
Ribbon	diagram	of	a	TCR	displayed	from	the	side	with	the	
constant	 domains	 Cα	 and	 Cβ	 anchoring	 it	 to	 the	 cell	
membrane	and	its	CDR	loops	forming	the	antigen-binding	
site	on	 top	 (labeled	1,	2	and	3	 for	each	chain).	α-	and	β-
chain	are	colored	 in	pink	and	blue,	respectively.	Constant	
and	variable	domains	are	labeled	for	each	chain.	
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It is usually two of the six CDRs, CDR3α and CDR3β, that directly engage with the peptide 
and thus primarily convey specificity while CDR1α, CDR2α, CDR1β and CDR2β typically 
contact the peptide-presenting human leukocyte antigen (HLA) molecule, described in detail 
below [21]. Canonical docking of TCRs on peptide-HLA comprises interactions between the 
α-chain and the N-terminal peptide residues while the β-chain contacts the C-terminal part 
[22]. The vast TCR repertoire diversity is generated during T cell development when the 
germline-encoded V, (D) and J gene segments are randomly rearranged in each thymocyte to 
create both TCRα and TCRβ chains [23]. Besides the arbitrary combination of the gene 
segments it is the addition of palindromic sequences and random nucleotides at the junction 
of these segments that contribute to the diversity. The TCR complex is formed by 
congregation of the variable TCR with the invariant CD3 signaling complex, made up of the 
signaling molecules CD3γ, δ, ε and ζ, that is responsible for signal transduction from the 
triggered TCR into the cell. TCRs recognize antigenic peptides only if presented by human 
leukocyte antigen (HLA) molecules and during this process make contact with both the 
peptide and the HLA protein. 
HLA encoding genes are located on chromosome 6 in a highly polymorphic region of the 
human genome. HLA-A, HLA-B and HLA-C are the major HLA class I and HLA-DR, HLA-
DP and HLA-DQ the major HLA class II genes. HLA class I molecules are expressed on all 
nucleated cells and predominantly present endogenous antigens to CD8+ T cells while HLA 
class II expression mainly characterizes specialized antigen-presenting cells like DCs, 
macrophages and B cells which present exogenous antigens to CD4+ T cells. Both the 
structure of the HLA protein as well as the origin of the antigen differ between the two 
classes, which is also mirrored in the distinct processes of antigen processing and 
presentation.  
HLA class I molecules are composed of an alpha chain with three domains that is bound to 
the cell surface and the non-covalently linked β2-microglobulin. Two α-domains form the 
peptide-binding groove that commonly accommodates peptides with a usual length of 8-10 
amino acids (aa). The main source of these peptides is the proteasome, a large cytosolic 
complex that degrades proteins marked for destruction into small peptides, which are then via 
the transporter associated with antigen processing (TAP) protein selectively transported into 
the endoplasmic reticulum (ER). There, empty MHC class I molecules are with the help of a 
multi-protein peptide-loading complex loaded with peptides fitting into the binding groove. 
The peptide-HLA class I complexes are then transported via the Golgi apparatus to the cell 
membrane and exposed on the cell surface [24]. 
HLA class II proteins on the other hand are composed of the two non-covalently bound α- 
and β-chain that are both participating in forming the peptide-binding cleft. This cleft is 
created by two α-helixes bordering the antiparallel β-sheet that is forming its bottom. (Figure 
2). In contrast to the closed binding groove in HLA class I molecules, the one in HLA class II 
molecules is open at both ends and has been shown to present peptides that are 15-24 aa long. 
Still, the peptide core that is actually binding to HLA class II is usually around nine aa 
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residues long and stretches out through the whole molecule with specific residues occupying 
discrete binding pockets at positions P1, P4, P6, P7 and P9 of the molecule [25] (Figure 2).  
Figure	2:	Three-dimensional	structure	of	an	HLA	class	II	molecule	(PDB-ID:	5NI9,	[26]).	 
	α-and	 β-chain	 are	 coloured	 in	 salmon	 and	 turquoise,	 respectively.	 The	 peptide	 is	 omitted	 in	 both	 pictures.	
(Left)	 Ribbon	 diagram	 of	 HLA-DR4	 presented	 from	 the	 side.	 The	 peptide-binding	 cleft	 as	 well	 as	 the	 two	
domains	 for	 α-and	 β-chain	 are	 labeled.	 (Right)	 Top-view	 of	 the	 surface	 of	 HLA-DR4	 displaying	 the	 empty	
peptide-binding	cleft.	Depicted	are	the	binding	pockets	P1,	P4,	P6,	P7	and	P9.	
	
Other peptide residues point upwards out of the cleft towards the TCR. These residues are 
typically located at peptide positions p-1, p2, p3, p5 and p8 [27, 28] (Figure 3). Extracellular 
pathogens are phagocytosed by professional APCs and after fusion of the endocytic vesicles 
with lysosomes degraded into peptides. Simultaneously, HLA class II molecules are 
synthesized in the ER with the invariant chain (Ii) occupying the binding groove and 
stabilizing the whole protein. This whole complex is then loaded via the Golgi apparatus into 
a specific compartment called MHC class II compartment (MIIC) where Ii is digested until 
only the class II-associated Ii peptide (CLIP) is left [29]. This peptide is subsequently 
released from the groove by action of the chaperone HLA-DM, which after fusion of the 
MIIC and the peptide-containing vesicle also facilitates the binding of the pathogenic peptide 
to the cleft [24]. Once the peptides have been successfully loaded onto the HLA molecule, the 
complexes are transported to the cell membrane and exposed on the surface ready to be 
recognized by circulating CD4+ T cells [30]. 
 
	
Figure	3:	Schematic	cartoon	of	the	interaction	between	a	
TCR	and	a	pHLA-complex.		
	TCR	 and	 HLA	 class	 II	 are	 colored	 in	 orange	 and	 blue,	
respectively.	 Peptide	 residues	 p1,	 p4,	 p6,	 p7	 and	 p9	
(indicated	in	blue)	occupy	the	five	classical	binding	pockets	
whereas	 residues	p-1,	p2,	p3,	p5	and	p8	 (colored	 in	 light	
orange)	mainly	make	contact	with	the	TCR.	
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	These processes present the classical rules of antigen presentation on HLA class I and class II 
molecules. The concept of cross-presentation, however, entails certain exceptions to this 
traditional way of processing and presenting antigen and has for instance been described in 
specialized DCs that can present exogenous peptides on HLA class I molecules [31]. 
Notably, during the process of autophagy cross-presentation can also be observed in the 
context of HLA class II, when cytosol-derived peptides are loaded onto and presented by 
HLA class II molecules [32]. 	
T lymphocyte development and immunological tolerance 
All B and T lymphocytes develop from a common lymphoid progenitor cell that 
differentiates from hematopoietic stem cells in the bone marrow. While B cells undergo most 
of their development in the bone marrow, early lymphoid progenitors of T cells leave the 
bone marrow and migrate to the thymus for maturation. There, they expand and seed the 
thymus with immature thymocytes. Only around 2-4% of these cells will mature successfully 
and be able to leave the thymus as naïve T cells, which highlights the strictness of the 
selection process that is crucial for establishment of immunological tolerance [33]. Immature 
thymocytes pass several stages of development that can be distinguished by different states of 
TCR gene rearrangement and expression of certain surface molecules, like CD44 and CD25 
and finally even the CD3-T cell receptor complex or the co-receptors CD4 and CD8. At first, 
all thymocytes are double-negative (DN), i.e. not expressing CD4 or CD8 molecules and 
located primarily in the outer cortex region [34, 35]. With maturation these cells will migrate 
through the thymus and end up as mature thymocytes in the medulla. During the DN stage 
the first rearrangements of the TCRβ chain occur and if successful lead to pre-TCR-
expressing DN cells that proliferate, clonally expand and upregulate both CD4 and CD8 to 
become double-positive (DP) thymocytes. This is where the rearrangements of the α-chain 
are initiated. At this stage, all DP thymocytes expressing successfully rearranged TCRs in 
complex with the CD3 signaling complex undergo two specific selection processes termed 
positive and negative selection.  
Approximately 10-30% of all DP thymocytes are positively selected, meaning that their 
randomly rearranged TCR is able to recognize and engage with peptide-HLA complexes with 
at least low affinity [34, 35]. Positive selection is mediated by cortical epithelial cells 
expressing both HLA class I and class II molecules loaded with self-peptides. Depending on 
the nature of the HLA molecule their TCRs engaged with, thymocytes will then down-
regulate either CD4 or CD8 and differentiate into single-positive (SP) mature T cells. All 
thymocytes that during this first selection process do not bind to any peptide-HLA complex 
die in a process called “death by neglect” [36]. At the same time, DP and also SP thymocytes 
are subjected to negative selection that takes place in the medulla and results in apoptosis of 
cells that recognize peptide-HLA complexes with high affinity [34, 35]. Medullary stromal 
cells are specialized in expressing ubiquitous as well as otherwise tissue-restricted self-
antigens to ensure the removal of a wide range of autoreactive thymocytes in this step. The 
expression of most of these organ-specific self-antigens is made possible by the action of the 
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transcription factor AIRE (autoimmune regulator) that is predominantly active in medullary 
stromal cells [37, 38]. It has, however, been shown that at the cost of maintaining a wide 
repertoire to ensure protective immunity, certain self-reactive T cells can escape negative 
selection and are readily detected in healthy individuals [33, 39-41]. This might for instance 
be due to the fact that not all self-antigens are actually expressed in the thymus. The T cell 
repertoire created by positive and negative selection is thus largely but not completely self-
tolerant. Interestingly, it also contains a small population of CD4+ T cells, the regulatory T 
cells (Tregs) that display stronger TCR engagement to self-HLA compared to conventional 
thymocytes, but still not strong enough to be negatively selected [42]. These cells together 
with other mechanisms, like anergy or deletion, are crucial in creating peripheral tolerance to 
prevent mature self-reactive T cells from reacting to tissue-specific antigens.  
T cell differentiation 
Mature, naïve T cells that have left the thymus circulate the blood and peripheral lymphoid 
tissues waiting to encounter their cognate antigen. These cells thoroughly scan the surface of 
APCs in the lymph nodes and upon recognition of the peptide-HLA complex with their TCR 
get activated and engage more closely with the APC to receive additional signals important 
for survival and differentiation. These signals are mediated through engagement of the 
activating CD28 molecule on the T cell by co-stimulatory receptors CD80/CD86 on APCs 
and by the local cytokine milieu at the time of activation [43]. Differentiation into the distinct 
T effector cell subpopulations can take up to 4-5 days before the cells are actually able to 
leave the lymph node and get to the center of infection or inflammation [19]. Upon clearance 
of the threat most effector cells undergo controlled cell death while a small number of cells 
remain and turn into long-lasting memory cells. These memory cells can, upon reinfection 
with the same pathogen, be reactivated quickly and proliferate to exert their effector functions 
immediately [44].  
Activated CD8+ T cells or cytotoxic T lymphocytes (CTLs) harbor cytotoxic and cytolytic 
effector functions. CTLs recognize peptide-HLA class I complexes and are specialized in 
fighting intracellular infections by bacteria, viruses, protozoa etc. Their main mechanism of 
action is to induce apoptosis in the infected cell. This is achieved by the release of perforin in 
combination with granzymes and granulysins at the immunological synapse and/or by direct 
interaction via FasL and Fas on the target cell triggering the death-inducing signaling 
complex (DISC) [45]. Moreover, CTLs produce cytokines, including IFN-γ, TNF and 
lymphotoxin (LT)-α that can either directly affect the infected cells or activate other immune 
cells. 
In contrast to CTLs, CD4+ effector T cells can be divided into several functional subsets as 
defined by expression of specific master transcription factors and signature cytokines and 
thus also by diverse effector functions. The differentiation into these T helper (Th) cell 
subsets is dependent on the nature of the stimulus and the cytokine environment at the time of 
activation [46] (Figure 4). Interestingly, a certain extent of plasticity of some of the major 
subsets has recently been described [47-51]. The main T helper cell subsets described so far 
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are the classical Th1 and Th2 cells, IL-17 producing Th17 cells, IL-10 and transforming 
growth factor (TGF)-β producing induced regulatory T (iTreg) cells, FOXP3+ natural 
regulatory T (nTreg) cells and T follicular helper (Tfh) cells [52-58]. A couple of other T 
helper cell subsets have recently been identified and appear to harbor noteworthy features for 
the tenor of this thesis and are thus shortly mentioned below, like the Tfh-related T peripheral 
helper (Tph) cell subset and the tissue-resident memory T (Trm) cells [59, 60]. Other subsets 
not mentioned in detail here include the IL-9-secreting Th9 or the IL-22-producing Th22 cells 
[61-63]. 
 
Figure	4:	The	classical	view	of	T	helper	cell	differentiation.		
Naïve	CD4+	T	cells	differentiate	into	distinct	T	helper	cell	subsets	according	to	the	local	cytokine	milieu	(above	
the	arrow)	at	time	of	activation	by	the	antigen-presenting	cell.	Each	subset	is	characterized	by	expression	of	a	
master	transcription	factor	and	the	production	of	certain	signature	cytokines	here	indicated	on	the	right	next	
to	the	respective	subset.	(Adapted	from	O’Shea	and	Paul,	2010	[47])	
	
Th1 cells are primarily induced in the presence of IFN-γ and IL-12, which can be produced 
by NK cells or innate immune cells like macrophages and DCs [64, 65]. Signaling via the 
signal transducer and activator of transcription 1 (STAT1) induces the expression of the 
transcription factor T-bet which in turn promotes the expression of IFN-γ, the signature 
cytokine produced by Th1 cells [64]. Other cytokines readily produced by these cells are IL-2 
and TNF-α. Th1 cells are participating in the host defense against intracellular viral and 
bacterial pathogens by inducing antimicrobial activity in macrophages [65]. Of note, the 
development of certain autoimmune disorders has been attributed partially to aberrant Th1 
responses [66-68].  
Th2 cells on the other hand, discovered at the same time as Th1 cells, are dependent on IL-2 
and IL-4 for their differentiation. In contrast to Th1 cells, Th2 cells are pivotal in instructing 
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humoral immune responses against intestinal helminthes and extracellular bacteria by 
producing large amounts of IL-4, IL-5, IL-6, IL-10 and IL-13 [65, 69]. They express the 
transcription factor GATA3, which is crucial for production of the before-mentioned 
cytokines and at the same time suppresses transcription of IFN-γ [46, 64, 70]. Pathological 
activity of this subset contributes to allergic inflammation and asthma [71, 72].  
More recently discovered cells belonging to the Th17 lineage are important for immune 
reactions towards fungi and specific extracellular bacteria [64, 73-75]. These cells are 
characterized by the production of IL-17A, IL-17F and IL-22, which is mediated by the 
expression of the transcription factor RORγt [76, 77]. The presence of IL-6 and IL-1β is 
required for successful induction of this lineage while TGF-β and IL-23 are essential for 
survival and expansion of Th17 cells [61, 78-80]. Interestingly, research suggests an 
implication of Th17 cells in the pathogenesis of autoimmune diseases, mainly observed in 
experimental mouse models for multiple sclerosis (MS) and rheumatoid arthritis (RA) [81, 
82]. 
Besides the above-mentioned CD4+ regulatory T cells, also termed natural regulatory T cells 
(nTregs), that mature in the thymus and are released already expressing the transcription 
factor forkhead box protein 3 (FOXP3), there are regulatory T cells that develop in the 
periphery from naïve CD4+ precursors. These cells are dependent on the combined action of 
TGF-β and IL-2 for their differentiation and are called induced regulatory T cells [83-87]. 
Similarly to nTregs the master transcription factor defining iTregs is FOXP3 [88, 89]. Tregs 
are important in limiting immune responses by inhibiting pro-inflammatory effector T cell 
responses or T cell responses against self. They make use of different mechanisms to exert 
their function. One such mechanism involves the secretion of anti-inflammatory cytokines, 
such as IL-10 and TGF-β [90-94]. Considering their importance in limiting immune 
responses and preventing reaction against self, a dysregulation of Tregs could potentially 
contribute to chronic inflammation and autoimmunity [84, 95]. 
T follicular helper (Tfh) cells reside in follicular areas of lymphoid tissue and are crucial for 
the regulation of antigen-specific B cell immunity [56, 57, 96]. They are selectively induced 
in the presence of IL-6 and IL-21, which promote the expression of the master regulator 
transcription factor Bcl6 in these cells [97, 98]. Another hallmark of Tfh cells is the perpetual 
expression of the chemokine receptor CXCR5, which helps the cells localize to B cell 
follicles. There they can act on germinal center B cells and induce their differentiation to 
antibody-producing plasma or long-lived memory B cells, a process that is described in more 
detail below [56, 99]. Tfh cells primarily secrete IL-21 and IL-4 but also upregulate CD154 
(CD40L), which is critical for their interaction with the B cells [100-102]. Other mentionable 
markers expressed on Tfh cells include programmed cell death protein (PD)-1 and inducible 
T cell costimulator (ICOS) [103, 104]. Because of their importance in instructing B cells in 
the germinal centers, overactive or dysregulated Tfh cells could be involved in the 
pathogenesis of certain antibody-mediated autoimmune diseases such as systemic lupus 
erythematosus (SLE), Sjögren’s syndrome and RA [105].  
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Another T helper subset that is functionally very similar to Tfh cells has recently been 
described in the rheumatic joint [59]. These peripheral T helper (Tph) cells are defined as 
PD-1high CXCR5- T cells that by expressing factors like IL-21, CXCL13 and ICOS are 
geared to provide B cell help and induce plasma cell differentiation [106, 107]. In contrast to 
Tfh cells expressing the transcription factor Bcl6, Tph cells upregulate Blimp1, which is 
typically downregulated in Tfh cells. Another hallmark is the expression of the chemokine 
receptors CCR2 and CX3CR1 that allows Tph cells to directly migrate to inflamed sites, like 
the synovial joint. Tph cells have hitherto only been found in the synovial joint of RA 
patients. Nevertheless, it is very likely that this subset of cells is central also to other 
antibody-mediated autoimmune disorders [108]. 
Finally, during the last years an additional memory T cell subset has been identified, the so-
called tissue-resident memory T (Trm) cells. These cells have mainly been studied in barrier 
areas like skin and mucosa where they persist and provide rapid on-site immune protection 
against pathogens [60, 109-112]. Comparing mouse and human, as well as CD4 versus CD8, 
there is still a lack of studies investigating the exact phenotype of the CD4+ subsets in human 
tissue. Still, the activation marker CD69 and the lately identified transcription factor Hobit 
stand out in both CD4+ and CD8+ subsets [113, 114]. Autoreactive and anomalous activated 
resident memory cells may contribute to numerous human inflammatory diseases, including 
psoriasis and mycosis fungoides [115-117]. 
B lymphocytes and antibodies 
In contrast to T lymphocytes, B cells undergo their whole development including somatic 
recombination of the B cell receptor (BCR) genes and several checkpoints regarding 
tolerance in the bone marrow. After final maturation and migration to the spleen, the now 
mature but naïve B cells reside in special areas like the marginal zone or recirculate freely 
between lymphatic tissues [118]. B cells take up antigen via their B cell receptor and, upon 
internalization, get activated and can process it for presentation on their cell surface. The 
subsequently expressed peptide-HLA class II complexes are then recognized by TCRs on 
CD4+ T cells, the follicular helper T cells, that provide the first signal for activation. Upon 
engagement of other molecules like the co-stimulatory molecule CD40 on the B cell with its 
ligand CD40L, these Tfh cells release cytokines like IL-21 that eventually start the program 
for proliferation and final maturation into antibody-producing plasma cells or memory B cells 
[30]. This transformation takes place in structures called germinal centers and involves steps 
like antibody class switching and affinity maturation [119, 120]. It leads to the production of 
high-affinity class-switched antibodies or immunoglobulins (Igs) that can directly neutralize 
pathogens and toxins or opsonize them and facilitate their phagocytosis by other immune 
cells. The different classes of immunoglobulins include IgM and IgD, which are mainly 
expressed by naïve B cells, as well as IgG, IgA and IgE, that all have distinct functions in the 
body. Besides plasma cells there is a number of affinity-matured memory B cells that as their 
name implies are long-lasting and remain even after the inflammation is resolved. So, upon 
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re-encounter of a certain pathogen, these memory cells can proliferate immediately and 
produce high-affinity antibodies [121]. 
 
1.1.3 Autoimmunity 
The immune system is a complex, but well regulated entity that protects the host from an 
uncountable variety of pathogens. Based on its ability to recognize self, it typically and 
selectively targets foreign antigens. This self-tolerance is mainly conveyed by combined 
processes of central and peripheral tolerance, as discussed before. However, if self-tolerance 
fails, autoreactive immune cells start attacking the body’s own tissues and thus contribute to 
the development of chronic inflammation and autoimmunity [122, 123]. Although the exact 
mechanisms leading to these conditions are not completely understood and are likely to vary 
between different diseases, there are several processes that might be involved in the breach of 
tolerance. Tissue and cell damage are common features of e.g. bacterial infections and may 
result in an increased concentration of previously not exposed self-antigens [124]. 
Autoreactive immune cells that happen to be in this pro-inflammatory environment could 
then through a process termed bystander activation receive both activation signals and start 
proliferating [125]. Besides highly inducing the expression of co-stimulatory molecules, the 
inflammatory environment can have other effects, including increased and exacerbated post-
translational modification of native proteins. Since cells recognizing such post-translationally 
modified proteins are likely not to be purged in the thymus, these autoreactive immune cells 
might then start recognizing these previously absent neoantigens [126]. Notably, certain 
pathogens have also been shown to induce post-translational changes in native proteins that 
might then also lead to immune recognition and finally to autoimmunity [127]. Moreover, it 
has been implied that molecular mimicry could lead to activation of autoreactive immune 
cells that could after recognizing and being activated by the pathogenic antigen start cross-
reacting to a self-antigen that molecularly resembles the foreign target and continue to do so 
even after the clearance of the initial infection [128]. 
 
1.2 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a severe systemic, inflammatory disease affecting 0.5-1% of 
adults of all ethnicities worldwide with the prevalence in women being three times higher 
than in men [129, 130]. It is a complex autoimmune disorder that primarily affects small 
joints in hands and feet in a symmetrical pattern but can also involve larger joints, such as 
knees and shoulders. RA is characterized by inflammation and hyperplasia of the synovium, 
which is linked to an infiltration of immune cells, such as macrophages, neutrophils and 
CD4+ T and B cells. It leads – when uncontrolled active – to irreversible joint damage, 
disabilities, pain, fatigue as well as cardiovascular and other comorbidities [131]. These 
manifest in some patients in extra-articular disease symptoms such as vasculitis, pleuritis, 
pericarditis and pulmonary fibrosis and are associated with a shorter life expectancy [132, 
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133]. Several studies have also linked the incidence of certain types of cancer to RA, 
including an increased risk of lymphoma in patients with high disease activity [134-136]. 
Diagnosis and classification of RA is among other factors based on the presence of 
autoantibodies like rheumatoid factor (RF) and the RA-specific anti-citrullinated protein 
antibodies (ACPAs) in the serum of patients [137, 138]. The presence or absence of these 
autoantibodies define the two major subsets of RA, ACPA-positive and ACPA-negative RA. 
Approximately two-thirds of patients are diagnosed with seropositive RA, the subset for 
which we have more detailed knowledge regarding possible etiology and pathobiology.  
 
1.2.1 Pathogenesis (and risk factors) 
While the exact etiology of RA is still unknown, multiple risk factors have been identified 
and their interaction is believed to be decisive in the development of the disease. Among 
those are genetic and environmental factors, such as cigarette smoking and exposure to 
infectious agents [126]. These factors and the general biological mechanisms leading to RA 
will be briefly discussed in this subchapter. According to several twin studies conducted 
during the last decades on RA patients and their first-degree relatives, genetic factors 
contribute around 40-60% to disease development. A Swedish twin study published recently 
by Hensvold et al estimated the heritability for ACPA-positive RA to be 41% [139].  
Genetic susceptibility 
The most prominent and repeatedly confirmed genetic risk factor associated to RA is 
positioned in the highly polymorphic HLA region located on chromosome 6 in humans. The 
first connection of the genes encoded in this region to RA was identified in the late 1970’s by 
Peter Stastny, who performed studies on leukocytes from RA patients and healthy controls 
[140, 141]. Later on, this association was narrowed down to certain allelic variants of the 
highly polymorphic HLA-DRB1 gene that encodes the β-chain of antigen-presenting HLA-
DR molecules. Interestingly, these alleles all shared an amino acid sequence (aa70-74: 
QKRAA, QRRAAA, RRRAA) in their third hypervariable region and were thus termed 
“shared epitope” (SE) alleles [142]. The HLA SE alleles include HLA-DRB1*01:01, *01:02, 
*04:01, *04:04, *04:05, *04:08 and *10:01. Besides having a higher risk of developing RA in 
general, carriers of HLA-SE alleles are also more likely to have seropositive disease and 
suffer a more severe and erosive disease progression with extra-articular manifestations and 
major organ involvements [137, 143, 144]. In 2012, the genetic association of HLA-DRB1 to 
RA was then pinpointed even more specifically to four amino acid residues in the peptide-
binding groove: aa11 and 13, positioned in the antiparallel β-sheet forming the bottom of the 
groove and aa71 and 74 which are part of the original SE sequence [145]. This strong 
association between HLA class II alleles and RA indicated a direct involvement of adaptive 
immunity in the course of the disease. The association of several additional genes involved in 
activation or general functionality of T and B cells to RA confirmed this hypothesis. The 
second strongest genetic predisposition for RA is based on a polymorphism in the protein 
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tyrosine phosphatase non-receptor type 22 (PTPN22) gene that encodes the lymphoid 
tyrosine phosphatase (Lyp) involved in negative regulation of T cell activation [146-148]. 
Moreover, polymorphisms in genes like STAT4, TRAF1-C5 and CTLA-4, all of them 
important for T cell functionality, have been identified [147, 149, 150]. 
Of note, many of the genetic variants identified, such as the ones for HLA-DRB1 and 
PTPN22, are associated with RA regardless of the serological status, even if the association 
to ACPA-negative RA was weak [151]. However, certain genetic differences between 
seropositive and seronegative RA have been revealed, adding to the assumption that RA 
divides into different subsets with distinct genetic make-up and etiology [151-153]. 
Environmental risk factors 
As only around half of the risk for developing RA can be explained by genetic factors, the 
involvement of other risk elements mainly from the environment is obvious. The most 
established environmental risk factor associated with RA, and particularly with seropositive 
disease, is cigarette smoking [143, 154-159]. Moreover, the gene-environment interaction 
between HLA-SE alleles and smoking has been shown to evoke RA-specific immune 
reactions against citrullinated autoantigens, such as the production of ACPAs, hinting 
towards a possible model for the etiology of seropositive RA [126, 160]. 
Other risk factors mainly for ACPA-positive RA include the intake of dietary salt in smokers, 
obesity, female sex, the exposure to air pollution and the inhalation of textile or silica dust, as 
mediated by an occupational exposure to these compounds [161-165]. Also, the exposure to 
infectious agents, such as specific bacteria and viruses has frequently been discussed as a 
possible trigger and driving factor of RA. Herpes viruses, such as Epstein-Barr virus (EBV) 
and human herpes virus 6 (HHV-6) have been suggested in this regard [166, 167]. Another 
interesting fact that has been repeatedly discussed is the progression to RA-like pathologies 
upon Chikungunya virus infection [168, 169]. Furthermore, just a few years ago, a link 
between periodontitis (PD) and RA was established, as PD was shown to be more common 
and severe in established as well as newly diagnosed RA patients [170, 171]. The bacterium 
Porphyromonas gingivalis is among other oral pathogens a known cause for PD. This made 
the above-mentioned connection of PD to RA even more interesting as this bacterium is one 
of the only known bacteria to actually express peptidyl-arginine deiminases (PADs), the 
enzymes catalyzing the conversion step of arginine to citrulline [172, 173]. With a major 
subset of RA patients being characterized by autoantibodies against citrullinated proteins, 
citrullination seems to be a pivotal process in the pathogenesis in general and specifically for 
the immunological mechanisms underlying the disease. These mechanisms will be discussed 
in detail below. 
Finally besides environmental factors conveying risk of developing RA, there are some 
factors such as high socioeconomic status, moderate alcohol consumption, a diet including 
oily fish and the use of oral contraceptives that have been shown to be protective against 
development of RA [174-179]. 
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Disease course and biological mechanisms 
As mentioned above, there are two major subsets for RA that can be classified based on the 
presence or absence of ACPAs. As the seronegative form of RA is with regard to its etiology 
and development incompletely understood and likely to be a very heterogeneous subset, the 
model of the general disease course and pathogenesis presented here is specifically valid for 
ACPA-positive disease. Based on current knowledge, RA development occurs stepwise with 
each of the disease phases being characterized and defined by the interplay of different cell 
populations [139, 180, 181] (Figure 5).  
 
Figure	5:	Model	for	longitudinal	development	of	ACPA-positive	RA.	(Adapted	from	Smolen	et	al,	2018	[181])	
	
 RA development is triggered years before actual clinical onset of disease by the occurrence 
of environmental challenges in genetically predisposed individuals. It has been suggested that 
certain risk factors, such as cigarette smoke, silica dust and other stimuli can act on mucosal 
sites like the respiratory, the oral or the intestinal mucosa and lead to local immune activation 
and inflammation [126]. Nowadays, it is strongly believed that the disease originates at extra-
articular locations [182-184]. In the case of cigarette smoke, multiple changes in the lung 
mucosa are induced, like increased epithelial permeability and apoptosis of alveolar 
macrophages as well as activation of macrophages and DCs [185-187]. The activation of 
these innate immune cells results in production of pro-inflammatory mediators and 
chemoattractants that subsequently lead to infiltration of neutrophils and further propagation 
of inflammation. Notably, it has been shown that these environmental stimuli can influence 
mucosal cells and induce PAD-mediated citrullination of a series of proteins, including 
matrix and intracellular proteins [188-190]. Another source of citrullinated proteins can be 
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the formation of neutrophil extracellular traps (NETs) during NETosis [191, 192]. Examples 
of citrullinated proteins found in inflamed bronchial and lung tissues include histones, 
annexin, fibrinogen, collagen, vimentin, and α-enolase [193]. Citrullination or deimination is 
the post-translational conversion of the positively charged amino acid arginine to the non-
canonical, neutral citrulline (Figure 6). It is an enzymatic process that takes place 
ubiquitously during cell differentiation, apoptosis and inflammation [194, 195]. Interestingly, 
citrullinated proteins can also be detected during gingival inflammation [196]. Here, 
citrullination is likely to be mediated by P. gingivalis that actually expresses its own PAD 
enzymes [172]. These post-translationally modified proteins represent neoantigens that can be 
taken up and processed by activated mucosal DCs and thereafter presented on HLA SE 
molecules to T cells. This step takes place in regional lymph nodes or secondary lymphoid 
structures formed directly at the site of inflammation [197]. These structures also facilitate 
activation of both T and B cells at the mucosal site and thereby promote the generation of 
ACPA locally [171, 198]. Other post-translational protein modifications discussed in RA that 
can lead to autoantibody generation are acetylation or carbamylation [199].  
Figure	6:	Citrullination	is	an	enzymatic	process.		
Citrulline	is	formed	by	deimination	of	arginine	by	peptidyl-arginine	deiminase	(PAD)	and	requires	Ca2+	and	H20. 
	
These locally produced autoantibodies can then get into the circulation and be detected in the 
serum many years before disease onset [200-204]. The presence of circulating ACPAs can be 
used both as a diagnostic and when found in conjunction with musculoskeletal complaints 
even as a prognostic marker, associating with a more aggressive disease course characterized 
by severe joint damage and radiographic outcome [202, 205]. Some studies revealed 
pathogenicity of ACPAs by activating complement, stimulating macrophages and 
neutrophils, and inducing ostecolastogenesis [206-210]. Still, as ACPAs used in these 
experiments were all isolated from peripheral blood of patients with established RA, it is not 
definitely established if ACPAs from the pre-clinical phase would have the same effect. It has 
however been shown that shortly before clinical onset ACPA-producing B cells undergo 
affinity maturation and that epitope spreading takes place giving rise to several ACPA fine 
specificities [211, 212]. Also, the significant increase in the titers of these antibodies as well 
as the occurrence of pro-inflammatory cytokines and chemokines in the circulation represent 
signs of general immune activation in this pre-clinical period [203, 213]. A commonly 
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observed feature during that phase is arthralgia, joint pain albeit without actual signs of active 
inflammation [214]. This pre-clinical phase is thus characterized by symptomatic systemic 
autoimmunity and results in anti-citrulline immune responses immediately before the onset of 
synovitis.  
The exact mechanisms leading to the initiation of joint inflammation and thus onset of 
disease are still incompletely understood. A likely theory is that an ‘additional hit’, such as a 
trauma, virus infection and others can lead to non-specific synovial inflammation. This in 
turn can induce local citrullination, which results in accumulation of citrullinated 
autoantigens in the joint [195]. Some of these might then potentially be recognized by 
ACPAs as specific epitopes from e.g. citrullinated vimentin or citrullinated annexin, and have 
been shown to be shared between the lungs and the joint, corroborating this whole theory 
[193]. Moreover, it has been observed that antibodies against citrullinated vimentin can cause 
osteoclast activation and differentiation leading to secretion of chemoattractants and bone 
resorption [210]. Once in the joint, these antibodies can then spread and contribute to local 
inflammation by a range of mechanisms including, as mentioned above, immune complex 
formation, complement activation and stimulation of macrophages and neutrophils. In 
addition to autoantibodies, inflammatory cells, mainly CD4+ memory T cells and 
macrophages, can as a result of increased angiogenesis and vascular permeability easily 
infiltrate the joint [215-217]. There they either distribute in the synovial sublining or in case 
of T cells can also participate in forming secondary follicles and ectopic germinal centers 
where mature B cells can proliferate to antibody-producing cells that in turn can undergo 
affinity maturation directly in the tissue [218-220]. Even without the presence of these 
ectopic structures that only appear in around 20% of patients, there is local antibody 
production since also B cells, plasmablasts and plasma cells enter the joint and spread in the 
synovium, same as follicular DCs and mast cells [221]. This immune cell accumulation 
results in synovial swelling, pannus formation and ultimately cartilage and bone destruction 
[222, 223]. Concurrently, expansion of the synovial intimal lining is occurring, mainly 
through activation of both macrophage- and fibroblast-like synoviocytes (FLS) [224]. These 
cells perpetuate synovitis by creating a paracrine/autocrine loop and by producing a range of 
pro-inflammatory cytokines, such as IL-1, IL-6, IL-8, TNF as well as matrix-degrading 
enzymes (matrix metalloproteinases, MMPs), prostaglandins and leukotrienes [225]. 
Moreover, especially FLS can cause additional cartilage damage by invading adjacent 
articular structures and are even likely to propagate disease by migrating to other joints [226, 
227]. Once this destructive or chronic stage of disease is reached, it is mainly osteoclasts and 
synovial fibroblasts that are actively promoting cartilage and bone erosion while lymphocyte 
involvement is rather rare. Still, synovial fluid samples taken during periods of active 
inflammation can contain high numbers of both innate and adaptive immune cells and will to 
a certain extent reflect what is happening in the synovial compartment [228].  
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1.2.2 Diagnosis and therapeutic approaches 
Diagnosis 
RA is diagnosed based on a set of certain classification criteria published by the American 
Rheumatism Association (ARA) in 1987 [229] (Table 1).  
 
These are well suited for identifying patients with established disease and for distinguishing 
these from patients with other inflammatory rheumatic conditions. A patient is diagnosed 
with RA if at least 4 out of the 7 criteria are fulfilled and criteria 1-4 have been present for at 
least 6 weeks. For diagnosis of early stages of RA, however, these criteria are not suitable 
since patients at early stages of disease do not or rarely present with nodules, erosions and 
decalcifications. Consequently, this set of criteria was revised and updated to a score-based 
system jointly by the American College of Rheumatology (ACR) and the European League 
Against Rheumatism (EULAR) in 2010 and now allows the identification of individuals with 
early RA [230] (Table 2). The updated criteria include besides RF even ACPA as well as 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), both acute-phase 
reactants and thus indicators of ongoing inflammation. A score of at least 6 is sufficient for 
diagnosis of RA. 
 
 
 
 
Table	1.	The	ARA	1987	revised	criteria	for	the	classification	of	RA	
Criterion	 Definition	1.	Morning	stiffness	 In	and	around	joints,	lasting	at	least	1	hour	2.	Arthritis	of	3	or	more	joints	 At	least	3	or	more	joints	with	simultaneous	soft	tissue	swelling	or	fluid	in	14	areas:	PIP,	MCP,	wrist,	elbow,	knee,	ankle	and	MTP	joints	3.	Arthritis	of	hand	joints	 At	least	1	area	swollen	(as	defined	above)	in	a	wrist,	MCP,	or	PIP	joint	4.	Symmetric	arthritis	 Simultaneous	involvement	of	the	same	joint	areas	(as	defined	in	2)	on	both	sides	of	the	body		5.	Rheumatoid	nodules	 Subcutaneous	nodules,	over	bony	prominences,	or	extensor	surfaces,	or	in	juxta-articular	regions,	observed	by	a	physician	6.	Serum	rheumatoid	factor	 Demonstration	of	abnormal	amounts	of	serum	rheumatoid	factor	by	any	method	for	which	the	result	has	been	positive	in	<5%	of	normal	control	subjects	7.	Radiographic	changes	 Changes	on	hand	and	wrist	radiographs	must	include	erosions	or	unequivocal	bony	decalcification	localized	in	or	most	marked	adjacent	to	the	involved	joints	
PIP:	proximal	interphalangeal;	MCP:	metacarpophalangeal;	MTP:	metatarsophalangeal	
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Table	2.	The	2010	ACR/EULAR	classification	criteria	for	RA	
Category	 Score	
A.	Joint	involvement	 	
• 1	large	joint	(shoulder,	elbow,	hip,	knee	and	ankle)			 0	
• 2-10	large	joints	 1	
• 1-3	small	joints	(MTP	or	PIP	joints)	 2	
• 4-10	small	joints	 3	
• >	10	joints	(at	least	1	small	joint)	 5	
B.	Serology	 	
• Negative	RF	and	negative	ACPA	 0	
• Low-positive	RF	or	low-positive	ACPA	 2	
• High-positive	RF	or	high-positive	ACPA	 3	
C.	Acute-phase	reactants		 	
• Normal	CRP	and	normal	ESR	 0	
• Abnormal	CRP	or	abnormal	ESR			 1	
D.	Duration	of	symptoms	 	
• <	6	week	 0	
• ≥	6	weeks	 1	
CRP:	C-reactive	protein;	ESR:	erythrocyte	sedimentation	rate	
 
Therapeutic approaches 
Current treatment strategies for RA focus on reducing inflammation, slowing down or 
preventing joint damage, and ideally achieving clinical remission [231, 232]. To this end, 
early intensive treatment with disease modifying anti-rheumatic drugs (DMARDs), such as 
methotrexate (Mtx), sulfasalazine or leflunomide, is common. Besides specific anti-rheumatic 
drugs, many patients also receive non-steroidal anti-inflammatory drugs (NSAIDs) or 
glucocorticoids, mainly for pain relief and symptomatic treatment [233-235]. During the last 
decade, the use of so-called biologics or biological DMARDs changed RA therapy and its 
outcome immensely [236]. They commonly target molecules that play important roles during 
inflammation or modify the immune system in general. However, these biologics are only 
prescribed if the response to the first-line DMARD was unsatisfactory and will then be 
administered in combination with Mtx to prevent the formation of anti-drug antibodies 
(ADA) against these theoretically immunogenic reagents [232, 237]. Nowadays, there are 
several types of biologics available for the treatment of RA, such as TNF-blocking agents, 
agents that induce T cell inhibition or B cell depletion as well as cytokine inhibitors. TNF-
blockers are by far the largest group of biologics and include adalimumab, golimumab and 
infliximab, all monoclonal α-TNF antibodies, etanercept, a soluble TNF-receptor/IgG-Fc 
fusion protein and certolizumab pegol, a polyethylene-glycol-linked α-TNF antibody 
fragment [238]. By neutralizing TNF these drugs lead to a general downregulation of 
inflammatory processes, which has been shown to be effective in around 60% of patients. 
Patients failing to respond to a certain TNF-blocker are prescribed another TNF inhibitor or a 
biologic with a different mode of action [232]. An example for such a biologic is abatacept, a 
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CTLA-4/IgG1-Fc fusion protein that is targeting CD80/CD86 on APCs and by doing so 
prevents the interacting naïve T cell from receiving essential co-stimulatory signals through 
CD28 [239, 240]. Full activation of T cells and ultimately production of cytokines and B cell 
activation are thus not possible anymore, which again affects and limits inflammatory 
processes [241, 242]. Direct targeting of immune cells is a commonly used principle for 
biologics and in the case of rituximab, a chimeric monoclonal antibody against CD20, the 
target cells are pre- and mature B cells [243]. It induces B cell depletion through apoptotic 
cell death possibly mediated by complement- or antibody-dependent cellular cytotoxicity 
(ADCC). However, the precise mechanism of action of both rituximab and abatacept, 
remains unclear [244]. Of note, both abatacept and rituximab have been shown to delay 
radiographic progression in RA [245, 246]. Another type of biologics comprises cytokine 
inhibitors, such as tocilizumab, a monoclonal antibody targeting the IL-6 receptor [247]. The 
latest addition to the list of anti-rheumatic drugs is the so-called jakinibs, janus kinase (JAK) 
inhibitors [248, 249]. Tofacitinib and baracitinib operate intracellular by inhibiting specific 
JAKs, key proteins in the JAK/STAT signalling pathway that mediates the effects of a large 
number of pro-inflammatory cytokines [250]. 
 
1.2.3 Citrulline immunity 
Throughout the description of RA in this thesis, the involvement of adaptive immunity has 
been recurrently demonstrated. In this paragraph the main actors of the adaptive immune 
response in RA, T and B cells, will be discussed in more detail.  
Citrulline-reactive B cells and autoantibodies 
Ever since the discovery of autoantibodies in RA, B cells have been thought to play a more or 
less central role in the development of the disease. More than 70 years ago the first 
autoantibodies in RA, the so-called rheumatoid factor (RF), were described [251, 252]. RF is 
an antibody that recognizes the Fc portion of human IgG, which can lead to the formation of 
immune complexes and activation of complement system. And as is true for ACPAs, the 
occurrence of RF has been linked to a more severe disease course with extra-articular 
manifestations and bone erosion and can precede clinical onset of disease for decades [201, 
253-255]. Nevertheless, RF is not exclusively found in RA patients but can among others be 
associated with other autoimmune diseases such as Sjögren’s syndrome or infectious diseases 
including hepatitis and tuberculosis [256-258]. Further rheumatoid arthritis-specific 
autoantibodies, the antiperinuclear factor and anti-keratin antibodies, were identified in the 
1960s and 70s, respectively, and subsequently shown to actually share specificity for the 
same protein, filaggrin [259-261]. Shortly thereafter, it was demonstrated that all epitopes 
targeted by these antibodies contained the non-coding amino acid citrulline and the name 
anti-citrullinated protein antibodies (ACPA) was termed [262, 263]. A range of ACPA fine 
specificities all targeting citrullinated epitopes from a range of proteins has been described. 
These include the above-mentioned filaggrin, fibrinogen, vimentin, α-enolase, collagen type 
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II, histone H4, tenascin-C and many more [264-269]. Interestingly, a recent study suggested 
that some ACPAs are actually not specific for one antigen only, but can cross-react by 
recognizing certain amino acid motifs rather than protein-specific features [270]. ACPAs are 
present in 60-70% of RA patients and are for diagnostic reasons commonly measured using 
an anti-CCP (cyclic citrullinated peptide) ELISA [230, 271-273]. They are found in different 
isotypes, including IgM, IgA and several subtypes of IgG, such as IgG1, IgG2, IgG3 and 
IgG4 [274]. ACPAs can be studied after purification from plasma or synovial fluid while 
autoreactive ACPA-producing B cells can be identified and visualized by the use of B cell 
tetramers [275-277]. These reagents allow ex vivo analysis of the cells and, by combining this 
method with sequencing technologies, even make it possible to examine their BCRs and 
transcriptional profiles. 
CD4+ T cells 
The strong association described between the presence of certain HLA-DRB1 alleles and RA 
supported a role for CD4+ T cells in the pathogenesis of the disease early on. Moreover, 
many of the genes with specific allelic variants that are associated with RA actually encode 
proteins that are involved in T cell regulation or signaling, like PTPN22, STAT4, CTLA-4. 
The discovery of T cells infiltrating the inflamed joint and organizing in follicular structures 
as well as the extensive expression of HLA-DR molecules on synovial cells further 
confirmed the importance of CD4+ T cells [278, 279]. This also provides evidence for 
ongoing immune reactions with T cells being activated and exerting their function directly in 
the synovium. Besides producing pro-inflammatory cytokines including IFN-γ, IL-17 and 
TNF that promote activation and recruitment of macrophages and other inflammatory cells, T 
cells also provide so-called T cell-help to B cells, which can then lead to local production of 
specific autoantibodies, like ACPA. T cells are thus believed to play an important role in 
perpetuating inflammation. 
Over the years, different T helper subsets have been suggested to contribute to the 
pathogenesis of RA. In line with what is mentioned above, CD4+ T cells secreting IFN-γ and 
TNF-α, known as Th1 cells, have been detected in synovial fluid from RA patients with 
established disease [280-283]. Very recently even the production of GM-CSF in the 
rheumatic joint has been attributed to this T helper cell subset [284]. Moreover, CXCL9 and 
CXCL10, two chemoattractants eliciting their function by binding to CXCR3, the chemokine 
receptor defining Th1 cells, are enriched in the synovial joint [285]. Notably, the Th1 lineage-
inducing cytokines IL-12 and IFN-γ have been detected in synovial tissue of RA patients 
[286, 287]. Similarly, IL-17 as well as the cells producing this cytokine, so called Th17 cells, 
have been observed in the synovium of the rheumatic joint and been implicated in the 
pathogenesis of various other autoimmune diseases like SLE and psoriasis [288-293]. Besides 
stimulating FLS to express pro-inflammatory cytokines and inflammatory mediators, 
synovial IL-17 has been shown to induce bone resorption by stimulating the expression of the 
osteoclast differentiation factor RANKL [294, 295]. For this subset the cytokines pivotal for 
differentiation and maintenance, namely IL-6, IL-1β, IL-21, TGF-β and IL-23, have also been 
  21 
detected in RA synovial joints [80, 296, 297]. The importance of another T helper cell subset, 
the T follicular helper (Tfh) cells that are essential for germinal center development and B 
cell maturation is indisputable for the creation of functional humoral immunity. A 
dysregulation or overactivation of such cells is thus likely to promote the development of 
antibody-mediated autoimmune diseases, such as SLE, Sjögren’s syndrome and RA [105]. In 
RA patients, detection of high numbers of Tfh cells in the circulation and increased serum 
levels of IL-21 is paralleled by increased serum anti-CCP titers and disease severity [298-
302]. The presence of Tfh cells in synovial tissue has also been described, albeit at rather low 
frequencies, as CXCR5 expression on synovial CD4+ T cells is quite rare [59, 303]. Here, a 
recently discovered Tfh-like subset, the T peripheral helper (Tph) cells, has been proposed to 
take over the task of providing help to B cells in the rheumatic joint [59]. Besides high levels 
of PD-1, Tph cells have been shown to express MHC class II as well as CCR2 and CX3CR1 
on their surface, two chemokine receptors enabling their migration to sites of inflammation 
such as the rheumatic joint [59]. A role for the recently characterized tissue-resident memory 
(Trm) cells in RA is currently being discussed as Trm cells are believed to contribute to the 
maintenance of pathogenicity in autoimmune diseases and have actually been described in 
recurrent psoriatic skin lesions [115, 116]. So far, Trm cells have not been demonstrated in 
synovial joints of RA patients. However, several clinical and functional characteristics, like 
the long-term persistence of inflammation at the particular location, the joint, and of T cell 
clones with identical TCRs as well as the presence of CD4+ T cells expressing both PD-1 and 
CD69 in synovial fluid of RA patients, are pointing towards an involvement of this subset 
[304-307]. Another very interesting CD4+ T cell subset that has been described in the 
circulation of some RA patients comprises CD4+CD28null cells that express perforin, 
granzymes and NK cell activating receptors, like NKG2D, clearly displaying cytotoxic 
features [308-311]. While perforin-secreting CD4+ T cells have been demonstrated in 
synovial fluid and tissue, CD4+CD28null cells are less common in the rheumatic joint [311-
313]. Besides dysregulation and/or abnormal activation of the afore-mentioned CD4+ T cell 
subsets, it is mainly defects in regulatory mechanisms that have been implicated in the loss of 
self-tolerance and the origin of autoimmunity. Regulatory T (Treg) cells with impaired 
development or effector functions are being discussed in this regard, in particular [95].  
FOXP3+CD25+CD4+ T cells have been shown to accumulate in synovial fluid and tissue of 
RA patients and also demonstrated suppressive capacity in vitro [314, 315]. A conceivable 
explanation for this paradox could be the inhibition of Treg functions locally in the rheumatic 
joint, which is corroborated by the capacity of certain pro-inflammatory cytokines present in 
the inflamed synovial environment, such as e.g. IL-4, IL-6 and TNF, to inhibit regulatory T 
cell functions [316-319]. Another explanation could be the diminished frequency of T 
regulatory type 1 (Tr1) cells found in the circulation and synovial fluid of RA patients [320]. 
This small subset of regulatory T cells is mainly defined by the production of the anti-
inflammatory cytokine IL-10 and known to suppress antigen-specific effector T cells via 
cytokine-dependent mechanisms [321, 322]. 
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Whenever analyzing certain T cell subsets present at sites of inflammation, it is essential to 
take the possible accumulation and activation of bystander T cells into account. To be sure to 
study arthritogenic T cells in RA that are involved in the pathogenesis of the disease, it may 
thus be important to focus on antigen-specific T cells. In the course of the years, T cell 
reactivities against many proteins have been suggested in RA. The potential candidate 
autoantigens were mostly joint-specific proteins, such as type II collagen and aggrecan, but 
also ubiquitously expressed proteins including heat shock proteins such as the Ig binding 
protein (BiP) [323-326]. In most instances it was and still is the earlier identified 
autoantibodies and their specificities that guide the way towards which proteins to consider as 
RA-associated autoantigens and to screen for potential candidate peptides. The specific focus 
on citrullinated T cell epitopes came up in 2003 when Hill and colleagues demonstrated that 
following the conversion of an arginine to a citrulline residue in its peptide sequence a 
previously non-binding vimentin peptide could now be presented on HLA-DRB1*04:01 
molecules and elicit CD4+ T cell responses [327]. This led them to speculate that citrullinated 
peptides might be preferentially presented by HLA-DRB1 risk alleles containing the shared 
epitope. The molecular background behind this hypothesis is that these shared epitope 
residues, aa70-74, are located in a position on the HLA-DR β-chain where they can 
contribute to the fourth anchoring pocket (P4) of the antigen-binding groove (Figure 7). 
 
 
	
	
Figure	 7:	 Shared	 epitope	 (SE)	 residues	 form	
binding	pocket	P4	in	HLA-DR	molecules.	
Top-view	 of	 the	 surface	 of	 HLA-DRB1*04:01	
(PDB-ID:	 5NI9,	 [26])	 displaying	 the	 empty	
peptide-binding	 cleft.	 α-and	 β-chains	 are	
colored	 in	 salmon	 and	 turquoise,	 respectively.	
Depicted	are	the	binding	pockets	P1,	P4,	P6,	P7	
and	 P9	 as	well	 as	 the	 SE	 residues	 (aa70-74)	 as	
sticks	and	colored	in	blue.	
  
Due to the nature of the shared epitope amino acid side chains, this results in a positively 
charged P4 pocket and thus influences the selection of binding peptides by impairing 
accommodation of those with positively charged P4 docking amino acids and selecting for 
peptides with nonpolar or negatively charged amino acids at this position [328-330]. The 
citrullination of proteins or peptides would consequently enhance their HLA binding capacity 
and thus the presentation of epitopes compared to their native form, which could not have 
been presented. This scenario has hitherto been demonstrated for citrullinated peptides from 
vimentin, fibrinogen, α-enolase, aggrecan, type II collagen and cartilage intermediate layer 
protein (CILP) [327, 330-335]. For some of these citrullinated peptides, different versions of 
P1
P4
P6
P7
P9
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aggrecan and vimentin epitopes, high-resolution crystal structures have been determined in 
complex with a couple of HLA-DR4 SE molecules [334]. These crystal structures revealed 
that the citrulline nicely fits into the P4 pocket of these risk alleles whereas the arginine in the 
native peptide is not able to bind. Moreover, performing in vitro cultures and ex vivo analysis 
using HLA class II tetramers, CD4+ T cells specific for some of these citrullinated peptides 
have been observed in HLA-SE positive RA patients [330, 331, 333-335]. Nevertheless, the 
creation of such neoantigens is not limited to the presence of a citrulline in peptide position 
p4, but can potentially also be mediated by citrullination of peptide residues actually pointing 
towards and interacting with the TCR. This could then lead to engagement of T cells that 
specifically recognize the citrulline in the modified peptides. As it is still not known whether 
post-translationally modified and especially citrullinated antigens are expressed in the thymus 
during T cell development, it is possible that such citrulline-reactive T cells are present in the 
circulation as a consequence of not having been purged in the thymus.  
As described above, the possibility of citrulline immunity being elicited in extra-articular 
organs, like the lung or gum, by APCs presenting citrullinated neoantigens to T cells is very 
intriguing and assigns a crucial role in the initiation of disease to these autoreactive T cells. 
As the presence of such citrulline-reactive T cells has been described mainly in peripheral 
blood and primarily in patients with long-standing disease [334, 335], there is a clear need for 
further studies to assess the frequencies and phenotypes of these cells in other compartments, 
like the rheumatic joint and in patients closer to disease onset. Additionally, despite the wide 
range of both B and T cell specificities described in RA we are still lacking understanding for 
which specificities are important in the beginning and created early on and which are actually 
playing a role in perpetuating the disease. 
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2 OBJECTIVES 
Autoreactive T cells have been assigned a crucial role in RA pathogenesis and are an 
interesting target for antigen-specific immunotherapy. This however requires a detailed 
understanding of these citrulline-reactive T cells and their specific targets. The overall goal of 
this thesis was therefore to study citrulline-reactive T cells with a focus on their phenotype 
and on the precise interaction between their T cell receptors and the peptide-HLA complexes 
they recognize.  
 
Specific aims: 
• To examine functional T cell responses to citrullinated epitopes derived from the 
candidate antigen α-enolase and to compare their relevance in peripheral blood of 
patients with different HLA-DR SE alleles, namely HLA-DRB1*04:01, HLA-
DRB1*04:04 and HLA-DRB1*01 (Paper I). 
 
• To assess and compare frequency and phenotype of T cells recognizing native and 
citrullinated α-enolase at the site of inflammation versus the circulation in RA patients 
(Paper II). 
 
• To simultaneously characterize multiple specificities of autoreactive T cells ex vivo in 
early RA patients and to monitor such cells longitudinally (Paper III). 
 
• To study the clonality and transcriptomic profile of citrulline-reactive T cells in 
peripheral blood and synovial fluid of RA patients (Paper IV). 
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3 METHODOLOGICAL CONSIDERATIONS 
This section is meant to give a general overview and some thoughts on the main methods 
used in the studies comprised in this thesis. More detailed description of the specific methods 
can be found in the method sections of the each paper or manuscript. 
 
3.1 FUNCTIONAL T CELL ASSAYS 
CD4+ T cell responses can be studied using a variety of assays with most of them relying on 
in vitro culture in presence of certain stimuli, like antigenic peptide or protein or anti-
CD3/CD28 beads as a first step. Examples for commonly used read-outs are measurement of 
T cell activation and proliferation by 3H-thymidine incorporation or labeling with 
carboxyfluorescein diacetate succinimidyl ester (CFSE). Moreover, one can analyze cytokine 
secretion using assays like ELISA, ELISPOT or luminex or by performing intracellular 
cytokine staining for multicolour flow cytometry. 
In study I we decided to perform T cell stimulation assays based on the upregulation of 
CD154 (CD40L), which allow detection of recently activated CD4+ T cells [336]. By slightly 
adjusting this protocol and combining CD40L upregulation with production of the pro-
inflammatory cytokines IFN-γ and/or IL-17A, we were able to detect both naïve and memory 
CD4+ T cells reacting to the applied stimuli [333]. Shortly, peripheral blood mononuclear 
cells are stimulated with peptides for 5 days and after a short restimulation with the same 
peptides and anti-CD28 antibody (in the presence of Brefeldin A) on day 5 fixed, 
permeabilized and stained with antibodies to detect CD4+ T cells expressing CD40L, and 
simultaneously IFN-γ and/or IL-17A (Figure 8).  
 
Figure	8:	Activated	CD4+	T	cells	express	CD40L	and	certain	cytokines.	
Flow	cytometry	plots	depicting	recently	activated	CD4+	T	cells	gated	as	CD40L+	cytokine+	cells.	
	
Although this assay is very sensitive and allows detection of recently activated antigen-
specific CD4+ T cells, there are certain limitations to this assay when being applied to 
diseases treated with immunosuppressive drugs, as these have been shown to affect activated 
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T cells in their frequency as well as their capacity to produce cytokines [337, 338] and even 
directly lead to decreased expression of CD40L in rheumatoid arthritis [339].  
A general drawback of in vitro assays is that the cells are manipulated before being examined 
which actually makes it difficult to investigate in vivo features as compared to reactions to in 
vitro culturing and stimulation. 
 
3.2 HLA CLASS II TETRAMER 
Peptide-HLA tetramer staining technology has proved an invaluable method enabling direct 
quantification of antigen-specific T cells in peripheral blood and other samples of interest. 
Besides this, HLA tetramers make it possible to phenotypically and functionally characterize 
antigen-specific T cells ex vivo and to monitor T cell mediated immune responses [340]. 
Tetramerization of single peptide-loaded HLA molecules is based on the strong biotin-
streptavidin (SA) interaction. By using fluorescently labeled SA molecules these peptide-
HLA tetramers can then be utilized for flow cytometry analysis. Commonly used 
fluorophores for tetramers are phycoerythrin (PE) and allophycocyanin (APC) or tandem 
fluorophores based on either of these two molecules (Figure 9).  
 
 
	
	
	
	
	
Figure	 9:	 Schematic	 structure	 of	 a	 HLA	 class	 II	
tetramer.	
B:	 Biotin-binding	 site,	 SA-PE:	 streptavidin-PE.	
(Adapted	after	Nepom	et	al,	2002	[341])	
 
Nowadays, HLA class II tetramers are routinely employed in a range of settings, like allergy 
[342, 343], vaccination [344, 345] and autoimmune diseases [335, 346, 347] and are 
generally applicable to any condition or field with known antigenic targets and association 
with specific HLA alleles. Ex vivo analysis of rare antigen-specific CD4+ T cells, like naïve 
or auto-reactive T cells, was made possible by combining HLA class II tetramer staining with 
a magnetic enrichment technique first developed by Wucherpfennig and colleagues [348]. 
Still, a major limitation of this assay is the requirement for large samples, in the range of 20-
30 million mononuclear cells, per studied T cell epitope. The implementation of a multi-
tetramer approach, like shown in study III, to enable staining of several T cell specificities 
simultaneously, was thus an important objective.  
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Another constraint of this technique is the fact that it is only useful for peptides binding with 
medium to strong affinity to the HLA molecule. These peptides are usually loaded onto the 
HLA monomer in an extra step right before tetramerization. For this to be successful and to 
ultimately obtain functional tetramers, the strength of the interaction between peptide and 
HLA molecule has to be of a certain level. To verify this we routinely perform in vitro 
competition binding assays that show the capacity of a selected peptide to displace an 
established reference peptide. Only if this is given, we are confident that we can prepare 
stable and functional tetramers. 
 
3.3 RNAsequencing 
The emergence of RNA sequencing technologies and in recent years specifically of potent 
single-cell applications made it possible to accurately quantify gene expression in specific 
cell populations as well as in individual cells [349, 350]. For study IV we decided therefore to 
combine this technology with HLA class II tetramer staining and performed full 
transcriptomic analysis of tetramer-sorted single CD4+ T cells. From the range of assays 
available we choose the plate-based Smart-seq2 approach for the library preparation as this in 
contrast to droplet-based assays, like 10X Chromium, provides higher-quality libraries [351, 
352]. This is mainly due to the higher read-depth per cell and the fact that, by using the 
paired-end sequencing option, reads may be generated across the whole transcript length. It 
was therefore possible for us to perform full transcriptomic profile analysis as well as 
clonotypic analysis of the single cell-sorted antigen-specific CD4+ T cells using the TraCeR 
analysis pipeline [353]. 
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4 RESULTS AND DISCUSSION 
The main findings of the studies included in this thesis are summarized and briefly discussed 
in relation to one another in the following section. The attached manuscripts give a more 
detailed description of the studies. 
 
4.1 FUNCTIONAL AND STRUCTURAL CHARACTERIZATION OF A NOVEL α-
ENOLASE T CELL EPITOPE IN RHEUMATOID ARTHRITIS (PAPER I) 
As antibodies to citrullinated proteins (ACPAs) in RA patients are strongly associated with 
the so called HLA shared epitope alleles [142] and T cell epitopes have been identified from 
a range of these ACPA-targets [333, 354, 355], we aimed at examining functional T cell 
responses to citrullinated epitopes derived from the RA-associated autoantigen α-enolase. 
Guided by the hypothesis that different HLA-DR SE alleles could bias citrulline-based 
autoimmunity, we also set out to compare the relevance of these epitopes in peripheral blood 
of patients with different sets of these RA-associated HLA-DR alleles focusing on HLA-
DRB1*04:01, *04:04 and *01, the three most common alleles in the Swedish patient cohort. 
Comparing autoantibody levels towards CEP-1, the dominant citrullinated B cell epitope 
from α-enolase, in sera of RA patients from the Swedish EIRA cohort, we found these 
significantly elevated in HLA-DRB1*04:01-positive compared to *04:04- and *01-positive 
RA patients. Also, the frequency of RA patients being positive for anti-CEP-1 antibodies was 
highest among individuals with HLA-DRB1*04:01 allele versus the two other alleles (Paper 
I, Figure 1). These results indicated that T cell responses towards α-enolase-derived peptides 
could be stronger in HLA-DRB1*04:01-positive RA patients compared to *01- and *04:04-
positive RA patients. 
Based on an unbiased binding screen of overlapping 15-mer peptides covering the whole α-
enolase protein we selected the eight peptides that achieved the highest binding scores to 
HLA-DRB1*01, *04:01 and *04:04 for further analysis. All selected peptides had at least one 
arginine residue and when predicting the binding registries based on HLA-DR pocket 
preferences we found these residues to be located both within the binding groove at peptide 
position p2 or occupying pockets P4, P6 or P7 as well as outside the cleft at peptide positions 
p-2, p-1, p10, p11 or p12 (Paper I, Table I). Notably, only peptide pairs 11/cit11 and 
420/cit420 contained arginine/citrulline residues at position p4 that could occupy pocket P4 
which has been discussed as a preferential binding position for citrulline based on previous 
studies [334, 335]. For the remaining peptides the arginine/citrulline residues would either 
occupy pockets P6 or P7 or actually protrude out of the binding groove ready for interaction 
with landing TCRs. 
First of all we performed general binding assays to assess and compare binding capacities of 
the selected peptides to the different HLA-DR alleles. All peptides were tested both in their 
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native and citrullinated version for their capacity to displace established reference peptides in 
in vitro competition binding assays. Both native and citrullinated versions of peptides 26 and 
241 could outcompete the reference peptides and bind to all three HLA-DR alleles efficiently. 
Conversely, neither of the two versions of peptides 56 and 171 was able to displace the 
reference peptide in any of the three HLA-DR molecules. We observed a mixed situation for 
both 420/Cit420 and 326/Cit326 with the former competing successfully only with the 
reference peptide in HLA-DRB1*04:04 however not in the other two alleles. Both 326 and 
Cit326 on the other hand displaced the reference peptide in context of HLA-DRB1*04:01 and 
*04:04 but not in HLA-DRB1*01. Intriguingly, peptide 11 displayed a significantly enhanced 
capacity to replace the reference peptide in its citrullinated compared to the native form in the 
context of all three HLA-DR alleles. In contrast, citrullinated peptide 1 displayed reduced 
capacity to outcompete the reference peptide in HLA-DRB1*01:01 and was not able to 
replace it in neither the native nor the citrullinated form when tested in the context of HLA-
DRB1*04:01 and *04:04 (Paper I, Figure 2 and Table I). We thus demonstrate that in 
several cases citrullination can influence peptide binding and either enhance or reduce the 
binding affinity of peptides to HLA-DR alleles. Furthermore, we demonstrate that the three 
different HLA-DR alleles have diverse peptide preferences, which are likely to result from 
the difference in size of the HLA-DR binding pockets for each allele. 
Next, we assessed the level of T cell activation in primary cells from RA patients upon in 
vitro stimulation with the candidate peptides by examining CD40L upregulation in 
combination with production of IL-17A and IFN-γ. We detected significantly increased T cell 
responses towards peptide Cit26 compared to its native counterpart in HLA-DRB1*04:01-
positive patients as well as similar trends for peptides Cit11, Cit56, Cit241 and Cit420 (Paper 
I, Figure 4). Citrullination of peptides 1 and 326, on the other hand, led to a decrease in T 
cell responses. Notably, when comparing responses detected in patient samples with T cell 
responses in samples from HLA-DRB1*04:01-positive healthy individuals, we detected less 
cytokine production in the latter almost in range with the unstimulated threshold value 
(Paper I, Supplementary Figure 3). Stimulation experiments performed in presence of 
HLA-DR-, -DQ- or -DP-blocking antibodies confirmed the restriction to HLA-DR alleles as 
responses were only abolished by addition of HLA-DR-blocking antibodies and unchanged in 
presence of the other two HLA-blocking antibodies. We thus demonstrate a clear bias in 
HLA-DRB1*04:01-positive patients towards exhibition of T cell responses to citrullinated 
versions of peptides rather than native counterparts. In detail, although both native and 
citrullinated versions of peptide 26 bound well to all three HLA-DR alleles we did not 
observe the same functional bias towards the citrullinated peptide in patients with HLA-
DRB1*01 and *04:04. Moreover, apart from the small increase we detected in affinity to 
HLA-DRB1*04:01 for Cit26 versus its native counterpart, there were no other reasons for us 
to expect crucial differences in the structural features of both HLA-DRB1*04:01/peptide 
complexes considering that the post-translational modified (PTM) residue was predicted not 
to be directly interfering with binding to the HLA molecule.  
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Comparative analysis of the crystal structures of HLA-DRB1*04:01/26 and HLA-
DRB1*04:01/Cit26 confirmed this prediction showing that the peptides take prototypic 
conformations within the binding cleft and demonstrated that the only structural difference is 
the modification of arginine to citrulline while all other residues keep exactly the same 
conformation. As predicted, both arginine and citrulline were shown to be at position p2 in 
the peptide and to project towards the solvent readily available for interaction with TCRs 
(Figure 10, left). Due to the loss of positive charges when arginine is converted into citrulline, 
these TCRs would in case of HLA-DRB1*04:01/Cit26 face a complex with changed 
electrostatic potential compared to HLA-DRB1*04:01/26 (Paper I, Figure 5). This thus 
suggests that citrullination of peptide 26 creates a neoantigen that is recognized by 
autoreactive TCRs, showing high specificity for the citrulline residue in Cit26, that have not 
been eliminated during negative selection. 
 
Figure	10:	Citrullinated	residues	can	be	directly	recognized	by	TCRs.	
Schematic	cartoons	of	the	interaction	between	TCRs	(orange)	and	pHLA-DR-complexes	(blue).	Peptide	residues	
p1,	p4,	p6,	p7	and	p9	(indicated	with	blue	circles)	occupy	the	five	classical	binding	pockets	whereas	residues	p-
1,	p2,	p3,	p5	and	p8	mainly	make	contact	with	the	TCR.	The	position	of	citrulline	residues	in	α-enolase	peptides	
cit26-40	(left)	and	cit326-340	(right)	is	indicated	as	the	red	colored	residues	at	position	p2	and	p-1,	respectively.	
 
4.2 CITRULLINE-SPECIFIC MEMORY T CELLS ARE ENRICHED IN THE 
RHEUMATIC JOINT (PAPER II) 
Besides studying several peptides throughout the whole α-enolase protein in the context of 
three different HLA-DR shared epitope alleles, we decided to focus on HLA-DRB1*04:01, 
the most common HLA-DR allele among our Swedish population cohort [356] and to employ 
HLA class II tetramer technology to study one specific α-enolase epitope in more detail. This 
epitope, aa326-340, had previously been shown to bind to the HLA-DRB1*04:01 molecule 
both in its native as well as the citrullinated version [335]. The two peptides were presented 
equally well and were predicted to bind in a way that their arginine/citrulline residue would 
be located at peptide position p-1 preceding the main anchor residue that is occupying pocket 
P1. The unconventional location of the arginine/citrulline residue within these peptide-HLA 
complexes and the fact that such T cell epitopes have been less studied in RA made it 
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especially interesting for us to examine the T cells that would recognize and interact with 
these complexes.  
We thus set out to confirm the binding predictions that had been made for these peptides and 
determined the crystal structures of HLA-DRB1*04:01 in complex with both eno326-340 and 
cit-eno326-340 at a resolution of 1.33Å and 1.35Å, respectively (Paper II, Figure 1). Both 
structures demonstrate the peptides fully occupying the HLA-DRB1*04:01 binding cleft with 
residues p328I, p331A, p333N and p336S anchoring in pockets P1, P4, P6 and P9, 
respectively. As previously predicted the arginine/citrulline residues are located at position P-
1 in the HLA groove pointing slightly up towards the solvent and TCRs interacting with the 
complex (Figure 10, right). Conversion of the arginine residue p327R to citrulline does not 
lead to changes in the binding register nor the conformation of cit-eno326-340 but rather 
influences the electrostatic surface potential of the new complex (Paper II, Figure 1C). 
Similar to what was described for peptide eno26-40 upon citrullination in Paper I, the 
modification of the arginine leads to the removal of a positive charge and is likely to affect 
the T cell repertoire that is able to interact with the HLA-DRB1*04:01/cit-eno326-340 
complex. We thus hypothesize that citrullination of peptide eno326-340 creates a potential 
neoantigen that would then be recognized by entirely different T cells. Considering however 
the location of the citrulline residue in the peptide, there is certain room for possible cross-
reactivity of TCRs as the conformation of the peptide section stretching from p328I to p338N 
is nearly identical in both structures. 
Using HLA class II tetramers assembled with either the native or the citrullinated version of 
eno326-340, we screened peripheral blood samples from healthy control donors and RA 
patients as well as synovial fluid from RA patients for T cells specific for these peptides. 
Additionally, we included a positive control tetramer loaded with a peptide from influenza 
virus hemagglutinin (HA, aa306-318). We detected influenza-reactive T cells in all healthy 
control and RA patient PBMC samples at an average of 26 per million CD4+ T cells while T 
cells specific for the arginine-containing eno326-340 were detected in 12/18 RA patients with 
an average of four cells per million CD4+ and two per million in healthy individuals (Paper 
II, Figure 2C and D). We thus concluded that T cells recognizing the native eno326-340 are 
part of the normal T cell repertoire and not fully eliminated during negative selection in the 
thymus. This assumption was also confirmed by the fact that these T cells were primarily 
naïve with only around 20% of them being of a memory phenotype in peripheral blood in 
both healthy donors and RA patients (Paper II, Figure 2E). Therefore, in contrast to the 
influenza-specific T cells for which we found the majority to be CD45RO+ memory, the T 
cells reactive to native eno326-340 have not encountered their cognate antigen previously.  
Next, we investigated T cells specific for the citrullinated version of the epitope, cit-eno326-
340, and found these cells to be present in 3/11 healthy individuals implying that they are not 
commonly part of the normal T cell repertoire. 60% of RA patients presented cit-eno326- 
reactive CD4+ T cells in PB while only around 30% of healthy donors did. However, 
whenever detected in healthy controls, the frequencies were comparable to the ones detected 
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in RA. When examining the presence of these cells at the actual site of inflammation by 
screening synovial fluid of RA patients we detected them at significantly elevated levels and 
an average of 15 cit-eno326-340-specific T cells per million CD4+ T cells in around 50% of 
the patients (Paper II, Figure 3A and B). The majority of the citrulline-reactive cells found 
in the joint were of a memory phenotype indicating previous antigen-exposure and activation 
(Paper II, Figure 3C). In paired samples of peripheral blood and synovial fluid we could 
confirm these findings showing increased numbers of memory eno326-340-specific T cells in 
SF compared to PB. Also for cit-eno326-340-reactive T cells we could detect an increase in 
some of the patients with frequencies up to five times than that for the native peptide (Paper 
II, Figure 3E). Additionally, we detected α-enolase-specific T cells in inflamed synovial 
tissue that due to the limited cell numbers recovered from such biopsy material was stained 
with the tetramers after in vitro propagation with peptides and IL-2 (Paper II, Figure 3D). 
The fact that we found citrulline-reactive memory T cells not only elevated at the site of 
inflammation, in synovial fluid and synovial tissue, but also in the periphery supports the 
hypothesis that the primary activation of these cells might take place outside the joint, e.g. in 
the lung [126, 188, 198] or the gum [170, 357]. Triggered by some local insult, these cells 
might then start migrating to the joints where inflammation-induced extracellular 
citrullination leads to an abundant presence of citrullinated proteins that could cause 
reactivation of these citrulline-reactive memory T cells, which in turn then contribute to the 
maintenance of the inflammatory milieu. 
Based on our previous assumption that due to the N-terminal positioning of the differing 
residue p327R/Cit and the otherwise identical conformation of the C-terminal part of the two 
peptides there could be different types of T cells. On the one hand T cells that selectively 
recognize HLA-DRB1*04:01 in complex with either the native or the citrullinated peptide 
and on the other hand T cells that cross-react and interact with both complexes. To 
investigate this feature more in detail, we performed molecular modeling as well as additional 
functional stainings. First, we superposed the three-dimensional structures of three ternary 
complexes that all contained peptide-loaded HLA-DRB1*04:01 in complex with TCRs 
specific for a viral [20], a tumor-associated [358] and the MS-associated autoantigen myelin 
basic protein [359], respectively, with our crystal structure of HLA-DRB1*04:01/eno326-340 
(Paper II, Figure 4). This overlay clearly demonstrates that the α-chain of a TCR could 
make contact with peptide residue p327R and that the conformation of this residue is likely to 
change after TCR landing on the complex. Also, when colouring the main interaction surface 
area between TCR and HLA-DRB1*04:01 molecule found in these three crystal structures 
we see that the TCRs dock close to peptide residue p-1 that precedes the first anchor residue 
(Paper II, Figure 4A and B). The assembly of HLA-DRB1*04:01 tetramers with two 
different fluorophores allowed us to perform dual-colour tetramer stainings on in vitro 
propagated peripheral blood samples from HLA-DRB1*04:01-positive RA patients. That 
way we could demonstrate the existence of patients with double-positive, i.e. cross-reactive T 
cells (Paper II, Figure 5A), as well as patients that lack such cells but instead possess T cells 
recognizing either the native or the citrullinated peptide (Paper II, Figure 5B). We also 
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applied this staining strategy to a couple of synovial fluid samples obtained from RA patients 
and found T cells cross-reacting between HLA-DRB1*04:01/eno326-340 and HLA-
DRB1*04:01/cit-eno326-340 in one of the samples (Paper II, Figure 5D) affirming the in 
vitro finding in active disease. This partial cross-reactivity thus confirms our hypothesis on 
the existence of different types of TCRs recognizing α-enolase-derived peptides either by 
binding to the central part of the peptide-HLA complex and not contacting the amino acid at 
position p-1 or by directly interacting with this amino acid and so revealing distinct 
preferences for the positively charged arginine and the neutral citrulline residue, respectively. 
In conclusion, we demonstrated the presence of α-enolase-reactive T cells in peripheral 
blood, synovial fluid and synovial tissue of RA patients. We found these T cells to be specific 
for both the native and citrullinated peptide eno326-340, however found a higher frequency 
of memory phenotype amongst cit-eno326-340-specific T cells in the periphery and these 
cells to be enriched in the synovial joint. Therefore, to investigate processes and mechanisms 
of RA and autoimmunity in general, studying the site of inflammation is crucial. 
 
4.3 A MULTI-HLA CLASS II TETRAMER STAINING APPROACH REVEALS A 
CORRELATION BETWEEN PRESENCE OF CITRULLINE-SPECIFIC T 
CELLS AND DISEASE ACTIVITY IN EARLY RA PATIENTS (PAPER III) 
As shown in the previous study as well as in other autoimmune diseases [346, 347] and 
different settings, like allergy [342, 343] and vaccination [344, 345], HLA tetramer 
technology offers a neat way of quantifying and phenotypically characterizing rare antigen-
specific T cells [340]. However, when performing ex vivo tetramer staining with magnetic 
bead enrichment [348, 360], the major constraint is the need for large samples, usually in the 
range of 20-30 million mononuclear cells per epitope. Actually, one shortcoming of the 
previous study was the fact that we had to focus on one specific T cell epitope from one of 
the RA-associated candidate autoantigens. Inspired by a recently published approach making 
use of combinatorial HLA class II tetramer staining for immunodominant viral epitopes 
[361], we therefore set out to explore the possibility of developing a multi-tetramer assay that 
would allow the simultaneous investigation of numerous specificities and still keep the 
sensitivity to detect rare autoreactive CD4+ T cells. Since a number of citrullinated T cell 
targets in RA have recently been identified [330, 333, 335, 355, 362, 363], we selected eight 
HLA-DRB1*04:01-restricted T cell epitopes from some of the common candidate 
autoantigens, namely α-enolase, cartilage-intermediate layer protein (CILP), vimentin and 
fibrinogen beta chain (FGB). In addition to these citrullinated RA-associated self-peptides, 
we included two viral control peptides from influenza virus matrix proteins in our panel [344, 
364] (Paper III, Table 2). Besides testing the general sensitivity as well as the robustness of 
the multi-tetramer assay when applying it to samples with low frequencies of autoreactive 
CD4+ T cells, we also made use of it to study the specificity, phenotype and frequency of 
such cells in samples of more clinical interest. Here, we screened for citrulline-reactive T 
cells in lymph node (LN) core needle biopsies from arthralgia patients and compared them 
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with early, untreated RA patients. Additionally, we investigated PBMCs collected from early 
RA patients that were sampled at baseline, i.e. before any treatment and at the six months 
follow-up visit to study and characterize citrulline-specific T cells and to investigate whether 
there is a correlation between the presence of different specificities with disease onset or 
development.  
As others and we have previously demonstrated the presence of autoreactive CD4+ T cells at 
low frequencies in the circulation of both RA patients and healthy individuals [26, 335], we 
used peripheral blood samples from four HLA-DRB1*04:01-positive healthy donors and 
from a cross-sectional cohort of 14 HLA-DRB1*04:01-positive RA patients with long-
standing ACPA-positive disease to test the sensitivity of the approach. Besides this, we also 
examined the robustness of the detected data by running technical repeat experiments with 
aliquots from the same healthy donors and by assaying PBMCs obtained from the patients of 
the cross-sectional cohort from repeat blood draws (n=3) taken approximately 2-3 weeks 
apart. We found T cells specific for α-enolase, CILP and fibrinogen at frequencies between 1 
and 10 per million CD4+ T cells in all four individuals and could demonstrate an overall 
good correlation in the frequency of tetramer-positive cells between the repeat experiments 
(Paper III, Figure 1a). When examining the differentiation state of these cells determined by 
the simultaneous or singular surface expression of CD45RA and CCR7 [365], we found the 
majority of the autoreactive T cells displaying a naïve phenotype and only some being central 
memory T cells. Conversely but expectedly, T cells specific for influenza, the positive 
control, were detected in all healthy controls at a frequency of 20 to 1000 cells per million 
CD4+ T cells. All of them were of a memory phenotype and distributed almost evenly among 
central memory and effector memory type T cells (Paper III, Figure 1b and c). The 
frequency of citrulline-specific T cells detected in the cross-sectional RA patient cohort was 
similar to the one observed in the healthy controls. However, not all specificities were present 
in all patients, α-enolase-reactive T cells e.g. were detected in less than 60% of the patients. 
For most patients we could reliably demonstrate the specificities in the repeat blood draws 
whereas for some we found citrulline-specific T cells only in one or two of the three samples 
(Paper III, Figure 2a). Examining the differentiation state of the autoreactive CD4+ T cells 
on the other hand, we again detected mainly naïve or central memory type T cells but we 
also, albeit to a lower extent, found citrulline-specific T cells with an effector memory or 
terminal effector memory phenotype (Paper III, Figure 2b). Since we included antibodies 
against several chemokine receptors and other activation markers in the panel we were able to 
investigate the phenotype of these cells in more detail. Compared to the influenza-specific T 
cells and the general CD4 population, we found an increased percentage of CXCR3+ cells as 
well as CD25+ and CCR6+ cells among the citrulline-reactive T cells. Surprisingly, CXCR5 
was expressed on 50-60% of both influenza- and CILP/fibrinogen-reactive cells but only on 
around 30% of the α-enolase-specific T cells (Paper III, Figure 2c). 
Next, we applied the panel to cells obtained from LN biopsies performed on five HLA-
DRB1*04:01-positive arthralgia patients with elevated RF and ACPA levels and five early 
RA patients naïve to treatment with biologics. We also included one patient with 
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undifferentiated arthritis and one healthy individual. As the cell numbers recovered from the 
core needle biopsy material were limited, we decided to analyse the cells after a short five 
day in vitro expansion with PHA and IL-2. Citrulline-reactive CD4+ T cells were detected in 
all individuals albeit in varying numbers of specificities (Paper III, Figure 3). It should also 
be noted that due to the in vitro expansion we could not calculate the original frequencies nor 
analyse the unmanipulated phenotypes for the detected cells. 
Additionally, we investigated PBMCs collected from ten early RA patients enrolled in the 
LURA study at the Karolinska University Hospital [198]. These HLA-DRB1*04:01-positive 
patients were sampled at baseline, i.e. at time of RA diagnosis before any treatment and at the 
six months follow-up visit to study and characterize citrulline-specific T cells at both time 
points. In general, we detected influenza- and citrulline-specific T cells with frequencies 
ranging from 10 to 230 influenza-specific cells per million CD4+ cells and 1 to 7 citrulline-
reactive cells per million CD4+ T cells at both baseline and following six months of standard 
anti-rheumatic treatment in this early RA cohort (Paper III, Figure 4a and b). All but one 
patient, who later turned out to be seronegative for both RF and ACPA, had citrulline-specific 
T cells (Paper III, Figure 4b and Table 2). Among the three citrulline-specificities we 
tested for in these patients, vimentin was the one found least often with 3 and 4 out of 10 
patients for baseline and follow-up, respectively, while both CILP/fibrinogen- and α-enolase-
reactive T cells were detected in 5-6 out of 10 patients (Paper III, Figure 4b). Interestingly, 
from the five patients for whom we demonstrated a decreased frequency of citrulline-reactive 
T cells at 6 months follow-up compared to baseline, three achieved clinical remission with a 
DAS28-value <2.6. Notably, although one patient that also showed a decline in frequency of 
citrulline-reactive CD4+ T cells at follow-up could due to a missing DAS28-value at 6m not 
be classified as responder or non-responder, we suggest based on low DAS28-values at 3 and 
13m and on the fact that no change in therapy was administered at the 6m follow-up visit that 
this patient probably had low disease activity and even achieved remission (Paper III, 
Figure 4a and Table 2). Considering the number of patients included here it is difficult to 
draw any conclusions, however the results from this small study imply that clinical response 
in some patients may result from a restriction of the autoimmune component of the disease. 
We also demonstrate the benefit of having different HLA class II tetramers in various 
channels in order to make specific sub-analyses. The analysis of CD45RA and CCR7 
expression on the antigen-specific T cells revealed for instance a decrease in the frequency of 
memory phenotypes among α-enolase- and CILP/fibrinogen-specific T cells from baseline to 
follow-up, while vimentin-reactive T cells displayed a trend for increased central memory 
and decreased naïve T cells (Paper III, Figure 4c and Supplementary Figure 2c). 
Examining the other phenotypic markers, we could demonstrate expression of CXCR5, 
CXCR3 and CCR6 on some of the autoreactive T cells. CXCR5 was most frequently 
expressed among all specificities and also detected on around half of the influenza-specific T 
cells (Paper III, Supplementary Figure 3b). 
In conclusion, we demonstrated the presence of citrulline-reactive T cells in lymph node 
biopsies from arthralgia and early RA patients and found that early RA patients achieving 
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clinical remission after 6 months of standard anti-rheumatic treatment also had a decreased 
frequency of citrulline-specific T cells in their periphery. The multi-tetramer approach thus 
allows monitoring of auto-reactive T cells over time and their distinction and further 
characterization according to their specificity. 
 
4.4 TRANSCRIPTOMIC ANALYSIS REVEAL CYTOTOXIC FEATURES OF 
CITRULLINE-SPECIFIC CD4+ T CELLS IN RA PATIENTS (PAPER IV) 
As portrayed in study II and III, we can enumerate and phenotype citrulline-specific CD4+ T 
cells in peripheral blood and synovial fluid from RA patients by flow cytometry using HLA 
class II tetramers. The phenotypic characterization of these cells, however, is necessarily 
driven and limited by specific hypotheses and prerequisite knowledge. An unbiased approach 
to conceive the incompletely understood nature of autoreactive and specifically for RA of 
citrulline-specific CD4+ T cells is therefore needed. In case of RA, where the major site of 
inflammation, the rheumatic joint, is enriched in memory and effector T cells [366, 367], it 
would be particularly interesting to investigate the contribution of bystander versus locally 
activated, i.e. autoreactive, T cells to the inflammatory milieu. We thus set out to perform 
single cell transcriptomic analysis of both citrulline- and virus-specific CD4+ T cells sorted 
from peripheral blood and synovial fluid from HLA-DRB1*04:01-positive RA patients. 
Using HLA-DRB1*04:01 tetramer, we sorted T cells specific for three citrullinated peptides, 
two from α-enolase, cit-eno26-40 and cit-eno326340 and one from cartilage intermediate 
layer protein, cit-CILP297-311, and (for the majority of the samples) simultaneously T cells 
reactive to two commonly used control peptides from influenza matrix proteins, HA306-318 
[364] and MP97-116 [344]. For this study we chose to employ Smart-seq2 sequencing [351] 
as it allows both full transcriptomic and using the TraCeR analysis pipeline [353] even whole 
α/β TCR sequence analysis.  
First, we assessed the general feasibility of generating efficient single cell transcriptomic data 
from antigen-specific CD4+ T cells isolated using HLA class II tetramer from frozen PBMC 
and SFMC samples. For this we single cell-sorted influenza-specific CD4+ T cells from 
peripheral blood from a HLA-DRB1*04:01-positive healthy donor and citrulline-reactive 
CD4+ T cells from PBMCs from one RA patient as well as from paired PBMC and SFMC 
samples from a second RA patient (Paper IV, Figure 1A). In general, the recovery of 
transcriptomic information was efficient throughout the tested samples with more than 97% 
of antigen-specific T cells sorted from peripheral blood and around 70% of cells from 
synovial fluid having whole transcriptome information. We also recovered fully rearranged 
TCRα and β sequences from many of the sorted cells from peripheral blood and to a lesser 
extent also from synovial fluid cells (Paper IV, Table 1) and could even identify common 
TCR sequences within samples indicating expanded CD4+ T cell clones (Paper IV, Figure 
1B). With this we confirmed the feasibility of combining HLA class II tetramer sorting of 
CD4+ T cells from frozen peripheral blood and synovial fluid cell samples with Smart-seq2 
sequencing. 
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Next, we set out to investigate and compare the transcriptomic profiles of autoreactive versus 
influenza-specific memory T cells in the periphery and at the site of inflammation. For this 
we analysed paired peripheral blood and synovial fluid samples from three RA patients and 
single PBMC and SFMC samples, respectively, from two other patients. Additionally, we 
had the possibility to examine these antigen-specific T cells longitudinally as we included a 
blood sample taken one year after the paired samples from one of the patients included in the 
first data set (Paper IV, Supplementary Table 1). As recovery of TCRα and β sequences 
and of whole transcriptome information varied among samples, we decided to examine each 
sample individually (Paper IV, Table 2). 
Principal component analysis (PCA) performed on all the sorted cells from all patients 
combined showed that most variation arises in-between individuals and that cells from the 
same patients largely coincided. Still, for paired samples we detected subtle differences 
between cells originating from the two compartments and found that cells generally group 
according to their origin (Paper IV, Figure 2A). When then focusing on the actual variation 
in the transcriptomic profile between citrulline- and influenza-specific CD4+ T cells we 
found these cells mainly clustering according to their specificity in both peripheral blood and 
synovial fluid (Paper IV, Figure 2B and C). Among the differentially expressed genes 
(DEGs) defining the more citrulline-specific cell cluster in peripheral blood of RA patient #2 
we found several genes distinctive of cytotoxic and cytolytic T lymphocytes, like granzymes 
GZMH, GZMB and GZMA, NKG (natural killer cell protein 7) and PRF1 (perforin-1). Also 
when running EnrichR, a gene ontology (GO) analysis tool defining biological processes and 
pathways associated to a specific gene list [368, 369], the terms “granzyme-mediated 
apoptotic signaling pathway” and “apoptotic process” are highlighted and transcription 
factor-encoding genes ZNF683 (Hobit) and EOMES (Eomesodermin) are pointed out as 
primarily associated to this cluster (Paper IV, Supplementary Figure 3A). Of note, both 
Hobit and Eomesodermin have been implicated in cytotoxic CD4+ T cell function in humans 
[370, 371] and even linked to RA patients with a certain genetic risk allele [313]. Similarly, 
in cells sorted from SFMCs from patient #3, we detected two clusters one comprising mainly 
citrulline- and the other influenza-reactive T cells (Paper IV, Figure 2C). Genes upregulated 
in the virus-specific cluster were predominantly HLA class II genes like HLA-DMA, HLA-
DRA and several alleles of HLA-DRB while in the citrulline-cluster we found a number of 
cells highly expressing CD69, which is a marker for recent activation but also found on the 
recently described tissue-resident memory T cells (Trm). So far these results imply that 
specific transcriptional signatures, pointing towards cytotoxic effector functions and possibly 
also towards a resident memory phenotype, are uniquely found in citrulline-specific CD4+ T 
cells. 
Thereafter, we focused on the paired peripheral blood and synovial fluid samples from RA 
patients #2, #4 and #5 and compared transcriptomic profiles of citrulline- and influenza-
reactive T cells between the two compartments. The citrulline-specific T cells grouped in all 
patients in at least two clusters, nicely segregating peripheral from joint-derived cells (Paper 
IV, Figure 3, left panels). In detail, we found GZMB specifically upregulated in synovial 
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fluid cells from one of the patients again underlining the presence of cytotoxic features in 
citrulline-specific CD4+ T cells (Paper IV, Figure 3B), We also identified S100A11 as a 
common denominator gene in the synovial fluid cell clusters of the two other patients (Paper 
IV, Figure 3A and C). Encoding calgizzarin, a member of the S100 family of proteins, 
S100A11 has recently been shown to be expressed in synovial joints of RA patients and even 
been correlated to disease activity and anti-CCP positivity [372], its specific function, 
however, is currently unknown. Based on the association between S100A11 and the 
ontological term “granzyme-mediated apoptotic signaling pathway” that is proposed when 
running the DEGs identified for one of the synovial fluid clusters (Paper IV, 
Supplementary Figure 3F), it is tempting to suggest a role for it in this process. 
Interestingly, we could show by isolating citrulline-specific CD4+ T cells from peripheral 
blood taken at two time points separated by one year that these cells kept the same 
transcriptomic profile. This demonstrates both the stability of this phenotype over time as 
well as the robustness of the single cell RNA sequencing technique. Examining and 
comparing the expression pattern of the cytotoxic genes we found upregulated in citrulline-
specific compared to influenza-reactive CD4+ T cells at one of the time points (Paper IV, 
Figure 2B), we observed these genes to be expressed also in citrulline-reactive CD4+ T cells 
at the second time point and even to a lower extent in citrulline-reactive T cells at the site of 
inflammation (Paper IV, Figure 5).  
Altogether these results consistently indicate cytotoxic characteristics of citrulline-reactive 
CD4+ T cells both in the periphery and at the site of inflammation for a subset of RA 
patients. Although the contribution of cytotoxic CD4+ T cells to RA pathogenesis has been 
proposed [308, 309, 311], a cytotoxic phenotype of citrulline-reactive CD4+ T cells has not 
been demonstrated before. To a smaller extent we also detected features of resident memory 
T cells in the citrulline-reactive CD4+ T cells in the synovial fluid of one patient. These 
included the upregulated expression of CD69 compared to influenza-specific T cells as well 
as the association to the transcription factor Hobit that has been implied in participating in the 
retention of T cells in the tissue [114]. Citrulline-specific CD4+ T cells might thus be 
secluded in the synovial joint, while virus-specific T cells would have the possibility to 
recirculate to the periphery. 
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5 CONCLUDING REMARKS AND PERSPECTIVES 
Over the course of the last decades, the frequency of autoimmune diseases has been 
increasing significantly [373]. 5-10% of people worldwide suffer from autoimmune diseases 
although some studies estimate the numbers to be as high as 20% [374]. The current 
treatment strategies for this disease group largely rely on immunosuppressive drugs that non-
specifically target certain parts of the adaptive immune system to control its aberrant immune 
responses. Despite of being effective in many patients, the patients that do not profit from 
such treatment as well as the common occurrence of undesirable side effects like infections, 
cancer and anti-drug antibodies pose a problem and point out the need for other treatment 
strategies [375].  
The theory of specific therapies that selectively target the pathogenic self-reactive cells has 
been around for a long time. The strong association with certain genes in the MHC class II 
region that is present in many autoimmune diseases led to autoreactive T cells being the 
major target of such antigen-specific immunotherapies. Effective immunotherapy is based on 
restoring immune tolerance to the antigen causing a disease and has been employed in the 
allergy field for more than a century [376, 377]. Understandably, the key determinant of such 
approaches is to focus on the relevant antigen(s) for tolerance induction.  
Many approaches taken in the past few years rely on direct injection of the self-epitopes, 
which has been shown effective and safe in MS, SLE, T1D and coeliac disease during several 
pre-clinical studies on animal models and phase I or II trials involving small groups of 
patients [378-381]. To directly involve APCs in this process and to make it easier for these 
cells to actually take up the peptides, biodegradable nanoparticles bearing the peptides of 
interest have been designed and shown to prevent disease onset and to modify its course in 
experimental autoimmune encephalomyelitis (EAE), a mouse model for MS [382]. These 
nanoparticles have very recently even been combined with complexes of peptide-loaded 
MHC class II molecules and shown to efficiently induce IL-10- and TGF-β-producing 
regulatory T cells that suppress APC functions and promote regulatory B cells in mouse 
models for RA and MS [383, 384]. 
Specifically in RA the use of ex vivo generated tolerogenic dendritic cells (tolDCs) that could 
induce tolerance by promoting T cell anergy or even apoptosis of autoreactive effector T cells 
or by stimulating the generation of cells with a regulatory phenotype has been proposed [385, 
386]. So far these cells have been loaded either with autologous synovial fluid or with a mix 
of citrullinated peptides derived from collagen type II, fibrinogen α and β chain and vimentin 
and demonstrated to be a safe and feasible therapy [387, 388]. In the study specifically 
utilizing the citrullinated epitopes the administration of these DCs even led to an increase in 
the ratio of regulatory to effector T cells and a decreased DAS28 score within a month [387]. 
This approach is currently being carried forward, focusing now on citrullinated epitopes as 
autoantigens in both cases. With patient recruitment still ongoing in one study and phase I 
trials just started in the beginning of this year for the other, first results regarding safety, 
tolerability and efficacy can be expected by the end of this or early next year.  
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With the general background of emerging immunotherapies and the knowledge that 
autoreactive CD4+ T cells recognizing citrullinated epitopes are of central importance in RA 
pathogenesis, this thesis was to provide deeper knowledge of citrulline-specific T cells, their 
phenotype and the interactions between their TCRs and the cognate peptide-HLA complexes 
on APCs. In the different studies within this thesis, we could confirm that citrullinated 
peptides from the candidate autoantigen α-enolase are readily presented on a range of HLA 
SE alleles. Interestingly, antigen presentation and the subsequent recognition by autoreactive 
CD4+ T cells was not necessarily dependent on a citrulline residue occupying binding pocket 
P4 of the HLA molecule but was also observed for peptides with citrulline residues at 
positions p-1 and p2. This underlines the importance of not focusing solely on the so-called 
P4-dockers when looking for possible citrullinated T cell epitopes. This notion was further 
confirmed by the description of a novel HLA-DRB1*10:01-restricted T cell epitope from 
citrullinated collagen type II harboring its citrulline residue at position p-2 that was shown to 
elicit T cell responses in RA patients [389]. Additionally, we show that patients’ T cell 
repertoires might differ essentially based on the HLA SE alleles the patients carry. This is due 
to the fact that these HLA alleles, albeit being closely related, contain certain aa differences 
that will affect the size and shape of the peptide-binding cleft and consequently the repertoire 
of presented peptides. Based on growing amount of data, it appears likely that RA is not 
mediated by one specific autoantigen, but rather entails many different T cell reactivities, the 
development of a multi-tetramer staining panel to assess multiple of these specificities 
simultaneously was an important step. Besides screening samples from early versus 
established RA patients to help solving the questions about relative importance or hierarchy 
among the different autoantigens this approach can possibly be useful for monitoring antigen-
specific T cells, specifically their frequencies and phenotype, in patients undergoing certain 
treatment, like the afore-mentioned antigen-specific immunotherapy. 
As autoimmune pathogenesis, genetics and the relevant autoantigens might differ from 
patient to patient or at least within different patient subgroups (e.g. different HLA-DR 
alleles), it is pivotal that such antigen-specific therapies are individualized and tailor-made up 
to a certain point. That could involve specific patient subgroups receiving a cocktail of 
several peptides or antigens of which some cover the antigen-specificities in certain patients 
while the rest are more specific for others. For this to be successful, it is however important to 
increase our knowledge of synovial and peripheral antigens even more. Considering the 
extra-articular triggering of disease these are likely to be derived from different organs. 
Studying the T cells reactive to such epitopes will moreover contribute to understanding their 
importance for the different phases of disease and also allow us e.g. to investigate if these T 
cells are public, i.e. present in the majority of patients, or more likely private. Also, the 
application of new technologies like single-cell RNAsequencing to study these autoreactive T 
cells is a way towards obtaining detailed understanding. In our studies of citrulline- and 
influenza-reactive CD4+ T cells in synovial fluid and peripheral blood it has e.g. led to the 
first time description of cytotoxic features in citrulline-specific CD4+ T cells in synovial 
fluid. New approaches can thus be very valuable in describing new pathways and 
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transcriptional programs that may potentially help in refining functional read-outs for T cell 
monitoring or even be the basis for the development of additional therapeutic strategies. 
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